USRE35862E - Delivery systems for pharmacological agents encapsulated with proteinoids - Google Patents

Delivery systems for pharmacological agents encapsulated with proteinoids Download PDF

Info

Publication number
USRE35862E
USRE35862E US08/252,979 US25297994A USRE35862E US RE35862 E USRE35862 E US RE35862E US 25297994 A US25297994 A US 25297994A US RE35862 E USRE35862 E US RE35862E
Authority
US
United States
Prior art keywords
microspheres
active agent
animal
microns
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/252,979
Inventor
Solomon Steiner
Robert Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emisphere Technologies Inc
Original Assignee
Emisphere Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Technologies Inc filed Critical Emisphere Technologies Inc
Priority to US08/252,979 priority Critical patent/USRE35862E/en
Priority claimed from US07/098,027 external-priority patent/US4925673A/en
Application granted granted Critical
Publication of USRE35862E publication Critical patent/USRE35862E/en
Assigned to MHR INSTITUTIONAL PARTNERS IIA LP reassignment MHR INSTITUTIONAL PARTNERS IIA LP SECURITY AGREEMENT Assignors: EMISPHERE TECHNOLOGIES, INC.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/559—Redox delivery systems, e.g. dihydropyridine pyridinium salt redox systems

Definitions

  • This invention relates to pharmacologically active agents which are encapsulated within protective proteinoid microspheres and the administration of same to warm blooded animals. It relates particularly to orally administered microspheres containing pharmacological agents which otherwise would be deactivated in the gastrointestinal tract.
  • the search in this area has been directed primarily in three directions; the co-administration of adjuvants, such as the resorcinols and the non-ionic surfactants polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether; the co-administration of enzymatic inhibitors, such as pancreatic trypsin inhibitor, diisopropylfluorophosphate (DFP) and trasylol; and the use of liposomes, such as water-in-oil-in-water emulsions which provide a protective layer of lipid around the encorporated pharmacological agent and which represent the most successful approach to date.
  • adjuvants such as the resorcinols and the non-ionic surfactants polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether
  • enzymatic inhibitors such as pancreatic trypsin inhibitor, diisopropylfluorophosphate (DFP) and tras
  • Additional objects of this invention are to provide methods of producing such delivery systems and of administering same to animals. It is a specific object to provide effective means for the oral delivery of insulin to diabetic mammals.
  • one aspect of this invention is a delivery system for an active pharmacological agent comprising said agent enclosed or encapsulated within proteinoid microspheres.
  • a second broad aspect of this invention is a method of encapsulating an active pharmacological agent comprising mixing said active agent with a pharmaceutically acceptable liquid and contacting said mixture with a proteinoid that interacts with said mixture to form hollow microspheres.
  • a third broad aspect of this invention is a method for targeting the release of a pharmacologically active agent in an animal comprising administering to said animal an effective amount of said active agent encapsulated within proteinoid microspheres, said micropheres being stable to the conditions encountered during migration from the point of introduction into said animal to a targeted release zone and being unstable at said zone.
  • Proteinoids which form the protective capsules of this invention, have been described as artificial polypeptides, as they are man-made condensation polymers produced by random or directed assembly of natural or synthetic aminoacids and/or small peptide chains. Following the discovery, in the late 1950's, that linear condensation polymers of mixed natural aminoacids could interact with water to form hollow microspheres, proteinoids have been the subject of extensive investigations of the origin of life. An excellent review of these investigations, along with extensive bibliographies, is found in Fox, S. W. and Dose, K., Molecular Evolution and the Origin of Life, Marcel Dekker, Inc., New York (1977), the disclosure of which is incorporated herein by reference.
  • proteinoids derived from the natural alpha-aminoacids (those found in animal or vegetable protein), as well as those incorporating other naturally occurring materials (such as) polynucleotides, phosphoric acid, iron and calcium), are non-toxic.
  • the size of the microspheres formed by contacting proteinoids with water or other liquid can be controlled within a range of from less that about one half micron to about ten microns or more by manipulating a variety of physical or chemical parameters, such as the pH, osmolarity or salt content of the liquid. It also has been observed that the proteinoids are far more resistant than proteins to cleavage by digestive enzymes.
  • the instant invention arose from the discovery that a pharmacologically active agent can be encapsulated within proteinoid microspheres simply by dissolving or suspending such agent in a pharmaceutically acceptable liquid, such as water or dimethyl sulfoxide, that interacts with that proteinoid to form microspheres.
  • a pharmaceutically acceptable liquid such as water or dimethyl sulfoxide
  • active agent bearing microspheres having diameters of less than about 10 microns are sufficiently small to pass readily through the gastrointestinal mucosa and enter the blood stream.
  • the preferred range for rapid diffusion is from about 0.5 to about 5.0 microns, as smaller sizes exhibit somewhat less stability and incorporate relatively little active agent and larger sizes diffuse less readily.
  • Particles of from about 5.0 to about 10 microns are, however, useful in admixture with those of the preferred range as their slower diffusion results in prolonged release of the active agent.
  • microspheres from acidic proteinoids which are stable in the highly acidic stomach (normal pH of from about 2 to about 6), but which dissolve in the near neutral blood.
  • Such systems are suitable for oral administration of peptide hormones, such as insulin, or heparin, which otherwise would be quickly destroyed in the stomach. They also are suitable for protecting the stomach from gastric irritants, such as aspirin.
  • aspirin containing microspheres When such aspirin containing microspheres are orally administered, they pass through the gastrointestinal mucosa and release the aspirin in the bloodstream far more rapidly than conventional enterically coated aspirin, which first must traverse the stomach and then must enter the bloodstream from the intestine after the enteric coating has dissolved.
  • a near neutral proteinoid microsphere system which is stable in the bloodstream, but which releases its content of pharmacological agent in response to the target organ environment, such as a higher or lower pH or the presence of a specific enzyme.
  • pharmacological agent such as a higher or lower pH or the presence of a specific enzyme.
  • Such near neutral systems must be introduced intravenously, unless the microspheres are sufficiently small to be encapsulated within larger proteinoid microspheres that are diffusible through the gastrointestinal mucosa and that are stable until they reach the bloodstream.
  • any pharmacological agent can be encapsulated within proteinoid microspheres, it obviously is of particular value for the protection of such agents which otherwise would be destroyed or rendered less effective by conditions encountered in the animal body before it reached its target zone.
  • Example 1 illustrates the preparation of an acidic thermal proteinoid that interacts with an aqueous solution of a pharmacologically active agent to encapsulate and protect that agent within hollow microspheres.
  • These microspheres exhibit stability in the presence of the digestive enzymes and acid of the stomach and, being predominantly less thin 5.0 microns in diameter, pass readily through the gastrointestinal mucosa into the weakly basic blood stream, where they dissolve and release the pharmacological agent.
  • a stirred mixture of 52.3 g of aspartic acid (0.4 moles), 42 g of arginine hydrochloride (0.2 moles), 26 g of isoleucine (0.2 moles) and 50 ml of glycerol is heated under nitrogen to 160° C. with the evolution of gas. The temperature then is maintained at 155° C. for 23 hours, after which the mixture is cooled to room temperature, extracted with 200 ml of 10 wt % aqueous sodium bicarbonate and the extract dialized through a collodion membrane against distilled water for 26 hours, the water being changed every six hours. The content of the dialysis tubes then is evaporated to dryness at 50° C. under vacuum to yield a glassy solid acidic proteinoid material, which is ground to a fine powder.
  • this powdered proteinoid is added to a mixture of 50 mg of porcine insulin crystals in 2 ml of distilled water and the mixture allowed to stand at room temperature until microspheres have formed.
  • the insulin bearing microspheres are separated by filtration, washed with pH 5.4 aqueous acetic acid and then resuspended in 2 ml of pH 5.4 aqueous acetic acid. Microscopic examination of this suspension reveals stable microspheres that are predominantly between 0.1 and 5.0 microns in diameter. When a portion of the suspension is neutralized to pH 7.4 with concentrated ammonium hydroxide, dissolution of the microspheres is immediately evident.
  • Each of three adult white rats having normal blood glucose levels is administered a dose of 0.35 ml of the insulin bearing microsphere suspension of Example 2b by a syringe inserted through the mouth and into the stomach. Following dosage, each of these animals exhibits a significant reduction in blood glucose, as measured in blood samples taken from the tail.
  • hollow microspheres suitable for encapsulating pharmacological agents can be formed from proteinoids derived from a single acidic or basic amino acid and as few as one other amino acid, a greater diversity of component amino acids often produces higher yields of uniform size microspheres within the desirable diameter range of 0.5 to 5.0 microns.
  • Example 2 illustrates the effectiveness, in producing a hypoglycemic effect in mammals, of the oral administration of insulin encapsulated within a proteinoid derived from 18 different amino acids.
  • a 250 ml filter flask containing 10 g of anhydrous dl-glutamic acid and 10 g of anhydrous dl-aspartic acid under nitrogen is heated in an oil bath at approximately 200° C. until the contents are molten.
  • an anhydrous equimolar mixture of the sixteen neutral and basic amino acids found in animal protein i.e., alanine, arginine, asparagine, cysteine, glycine, histadine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tyrosine, tryptophan and valine.
  • the resulting mixture is stirred with a glass rod and maintained at 200° C. under nitrogen for three hours.
  • the amber product is extracted with a saturated aqueous solution of sodium bicarbonate and the resulting solution dialyzed through a collodion membrane against distilled water at room temperature for 24 hours, the water being changed every 6 hours.
  • the content of the dialysis tubes then is acidified to pH 5.4 with concentrated acetic acid and centrifuged. After discarding the supernatant liquid, the insoluble solids are washed with pH 5.4 aqueous acetic acid and centrifuged again. This wash also is discarded and the solid proteinoid product is dried over silica gel overnight and then ground to a fine powder with mortar and pestle.
  • a mixture of 50 mg of porcine insulin crystals in 2 ml of distilled water is added to 35 mg of the dry powdered proteinoid of Example 2a and the mixture allowed to stand at room temperature until microspheres have formed. The mixture is then centrifuged for 15 minutes. After discarding the supernatant liquid, the remaining microspheres are washed once with pH 5.4 aqueous acetic acid at room temperature and centrifuged for an additional 15 minutes. The supernatant liquid again is discarded and the insulin bearing proteinoid microspheres are resuspended in 2 ml of pH 5.4 aqueous acetic acid. Microscopic examination of the suspension shows that the microspheres are predominantly between 0.5 and 5.0 microns in diameter.
  • effective insulin bearing proteinoid microspheres can be produced by contacting a dry powered acidic proteinoid, such as those of Examples 1a or 2a, with insulin suspended or dissolved in a wide variety of pharmaceutically acceptable liquids, including aqueous solutions of ethanol, isopropanol, terpenol, dimethyl sulfoxide, starch, Tweens 80 and cyclodextran.
  • a dry powered acidic proteinoid such as those of Examples 1a or 2a
  • insulin suspended or dissolved in a wide variety of pharmaceutically acceptable liquids including aqueous solutions of ethanol, isopropanol, terpenol, dimethyl sulfoxide, starch, Tweens 80 and cyclodextran.
  • Example 3 illustrates an especially preferred method of producing insulin bearing proteinoid microspheres which reliably produces high yields of microspheres that fall within the desirable diameter range of 0.5 to 5.0 microns and that are readily soluble at the pH of the targeted blood.
  • a flask containing 2 parts by weight or anhydrous 1-glutamic acid under a stream of nitrogen is heated in an oil bath at approximately 175° C. until the contents are molten.
  • To this is added 2 parts by weight of anhydrous 1-aspartic acid and one part by weight of an anhydrous equimolar mixture of the sixteen neutral and basic amino acids found in animal protein.
  • the resulting mixture is stirred with a glass rod and maintained at 175° C. under nitrogen for three hours.
  • the dark amber product is extracted with saturated aqueous sodium bicarbonate and the extract dialyzed through a collodion membrane against distilled water at room temperature for 24 hours, the water being changed every four hours.
  • the entire content of the dialysis tubes then is dried under vacuum at 65° and the residual solids are ground to a fine powder with mortar and pestle.
  • An aqueous solution of proteinoid is produced by mixing 35 mg of the powder of Example 3a per ml of water, adjusting the pH to 7.4 with concentrated aqueous sodium bicarbonate and removing any insoluble materials by filtration. One part by volume of this solids free solution of proteinoid then is rapidly injected into an equal volume of a freshly prepared 25 mg/ml solution of porcine insulin in pH 2.25 aqueous acetic acid. The mixture, which has a pH of approximately 3.5, is stirred in an ice bath for 15 minutes and filtered to separate the insulin bearing microspheres from the filtrate which is discarded.
  • microspheres After washing twice with pH 3.5 aqueous acetic acid, the microspheres are resuspended in 10 parts by volume of pH 3.5 aqueous acetic acid. Microscopic examination of a portion of this suspension shows a high yield of microspheres which are predominantly between 0.5 and 5.0 microns in diameter and which dissolve rapidly when the suspension is neutralized to pH 7.4 by the addition of concentrated aqueous sodium bicarbonate.
  • Example 4 dosages of the insulin bearing microsphere suspension of Example 3b are referred to as "insulin filled microspheres".
  • Microspheres which contain no encapsulated insulin are produced by repeating the procedure of Example 3b, except that the insulin is omitted during the formation of microspheres and the microspheres are suspended in a 2.5 mg/ml solution of porcine insulin in distilled water, rather than in dilute acetic acid.
  • Doses of the resulting suspension, which contain no insulin within the microspheres are referred to as "microspheres with external insulin”.
  • Dosages of the 2.5 mg/ml solution of porcine insulin alone are referred to as "raw insulin”.
  • Twelve male white rats each weighing approximately 500 g and havinng a normal blood glucose level, are arbitrarily assigned to two groups of three animals and a third group of six animals.
  • the three animals of group A are administered the insulin filled microspheres by gavage and the three animals of group B are similarly administered the microspheres with external insulin.
  • the six animals of group C similarly receive the raw insulin. All dosages are 1 ml/500 g of body weight and all animals are tested for blood glucose immediately before dosage and at intervals thereafter.
  • the average blood glucose level for the animals in each group is shown in Table 2.
  • Diabetes mellitis is induced in rats weighing approximately 300 g by giving each a 75 mg/kg body weight intravenous injection of streptozotocin. Ten rats which are observed to show consistently high blood glucose levels, polyuria and polydipsia and must be maintained on subcutaneous injections of porcine insulin are selected for this experiment.
  • diabetic rats Three of the diabetic rats are administered by gavage approximately 1 ml of the aqueous suspension of porcine insulin bearing acidic proteinoid microspheres of Example 3b.
  • a fourth diabetic rat has 3 ml of the suspension in 50 ml of tap water placed in its water bottle and this rat self administers his dose. All of the rats are food deprived for 12 hours prior to dosing. In all subjects, the oral administration of the microencapsulated insulin produces a significant and prolonged reduction in blood glucose levels.
  • the remaining six diabetic rats are arbitrarily assigned to three groups of two animals.
  • the animals of the first group are administered by gavage 1 ml of the aqueous suspension of porcine insulin bearing acidic proteinoid microspheres of Example 3b.
  • the animals of the second and third groups receive subcutaneous injections of 0.25 mg (6.5 I.U.) and 0.125 mg (3.25 I.U.), respectively, of porcine insulin.
  • Blood glucose measurements are made on all animals immediately before dosing and at intervals thereafter.
  • the animal groups are crossed over twice at one week intervals, so that all of the animals receive each of the insulin treatments.
  • the average percent decrease from baseline blood glucose levels for each treatment is shown in Table 3.
  • One ml of the aqueous suspension of porcine insulin bearing acidic proteinoid microspheres of Example 3b is administered by gavage into the stomach of each of three adult guinea pigs weighing approximately 800 g. Blood samples are taken immediately before and at intervals after administration of the dosage.
  • the blood samples from guinea pig #1 are tested for blood glucose, which drops from a predosage level of 160 mg/dl to 42 mg/dl in one half hour and to 25 mg/dl in 1.5 hours, where it remains for an additional 1.5 hours, at which time symptoms of insulin shock are observed and the animal is revived by orally administered glucose.
  • the blood samples from guinea pigs #2 and #3 are tested for porcine insulin with radioimmuno assay kits, which are marketed by Cambridge Medical Diagnostics.
  • This method which distinguishes between porcine and guinea pig insulin, shows that the predosage level of porcine insulin in the blood of both guinea pigs #2 and #3 is zero.
  • concentration peaks at 250 micrograms/ml one and one half hours after oral administration of the microspheres and in guinea pig #3 a peak of 240 micrograms/ml is reached in four hours.
  • Example 3b The procedure of Example 3b is repeated, except that the insulin filled microspheres are suspended in aqueous acetic acid having a pH of 2.25, rather than 3.5. A sealed vial of this suspension is stored at room temperature for 23 days.
  • the activity of the thus aged encapsulated insulin is tested by administering the suspension by gavage to the stomachs of adult rats which have been deprived of rood for eight hours and then measuring blood glucose levels at intervals after dosage. The results are shown in Table 4.
  • the aged suspension of encapsulated insulin is added to human serum and, employing a standard laboratory haemocytometer counting technique, the number of microspheres are counted immediately after mixing and at intervals thereafter.
  • Table 5 shows the number of microspheres observable as a function of time.
  • aqueous solution of heparin containing 250 mg/ml of heparin is adjusted to pH 4.5 by the addition of concentrated acetic acid.
  • 35 mg/ml of the dry powdered acidic proteinoid of Example 3a is added 35 mg/ml of the dry powdered acidic proteinoid of Example 3a and the mixture is allowed to stand at room temperature until microspheres have formed.
  • One part by volume of the mixture then is centrifuged and, after discarding the supernatant liquid, the heparin bearing microspheres are washed with pH 4.5 aqueous acetic acid, filtered and resuspended in pH 4.5 aqueous acetic acid, the suspension being made up to one part by volume.
  • Microscopic examination reveals that the microspheres are predominantly within the range of from about 0.1 to about 5 microns in diameter, with the majority being between 1 and 2 microns.
  • Rat #1 receives no treatment.
  • Rat #2 receives an intravenous injection of 250 mg of heparin in one ml of distilled water.
  • rats #3-7 has 1 ml of the aqueous suspension of heparin bearing microspheres of Example 8a introduced directly into the stomach by gavage.
  • the effect of heparin is determined using the Activated Partial Thromboplastin Time (APTT) test. This test measures the time necessary for a sample of serum taken from the tail vein to form a fibrin clot. The results for each rat at various times after dosing are shown in Table 6.
  • APTT Activated Partial Thromboplastin Time
  • coagulation time increases to a level comparable to that seen following an intravenous injection of heparin. It is clear from this data that heparin is delivered to the bloodstream in a physiologically meaningful and active fashion when encapsulated in acidic proteinoid microspheres and administered orally. It should be noted that the oral administration of far larger doses per unit of body weight of unprotected heparin to laboratory animals and humans produces no detectable increase in coagulation time.
  • aqueous solution of physostigmine containing 50 mg/ml of physostigmine is adjusted to pH 5 by the addition of concentrated acetic acid.
  • To one volume of this solution is added 100 mg per ml of the dry powdered acidic proteinoid of Example 3a and the mixture is allowed to stand at room temperature until microspheres have formed. It then is filtered, washed three times with pH 5 aqueous acetic acid and the separated microspheres are resuspended in one volume of pH 5 acetic acid. Microscopic examination reveals that the suspended microspheres are predominantly 0.5-5.0 microns in diameter.
  • Each of two normal rats weighing about 360 g is administered by gavage 3 ml of the suspension of physostigmine bearing microspheres. Within 30 minutes of dosage, both animals have died and each exhibits enlarged liver and peritoneal hemorrhage. These lethal oral dosages of microencapsulated physostigmine are calculated to be less than one percent of the LD 50 oral dosage of unprotected physostigmine in rats.
  • microsphere delivery system is similarly effective with a wide variety of other agents which are labile in the stomach invironment, including nitroglycerin, Salk polio vaccine, rubella vaccine and hepatitis B vaccine.
  • agents which are labile in the stomach invironment including nitroglycerin, Salk polio vaccine, rubella vaccine and hepatitis B vaccine.
  • pharmacological agents which could be deleteriously affected by even the mildly acidic conditions encountered during encapsulation within acidic proteinoid microspheres.
  • the following experiment demonstrates the ability of a basic proteinoid to form microspheres which encapsulate and protect one such extremely acid sensitive pharmacological agent, a dopamine derivative, from the hostile environment of the gastrointestinal tract, as well as to deliver that agent to the circulatory system, from which it penetrates the brain blood barrier and releases dopamine in the brain.
  • the dopamine derivative employed in this experiment is PR-21, which is a proprietary composition of acylated dopamine bonded to a reduced dihydropyridine/pyridinium salt type redox carrier which was developed by Pharmatek, Inc. and is described in U.S. Pat. No. 4,479,932.
  • the unprotected PR-21 composition is unstable anywhere in the gastrointestinal tract and is particularly sensitive to acid conditions. When injected intravenously into rats, significant amounts of the deacylated quaternary precursor of dopamine can be measured in the homogenized rat brain by the method of Bodir and Farog, Journal of Medicinal Chemistry, 26, 528 (1983).
  • a nitrogen swept mixture of two parts by weight of arginine, two parts by weight of lysine and one part by weight of an equimolar mixture of the sixteen neutral and acidic aminoacids found in animal protein is stirred and heated at 180° C. for 3 hours.
  • the cooled reaction mixture is extracted with pH 2.25 aqueous acetic acid and the extract is dialyzed through a collodion membrane against a large volume of distilled water at room temperature for 48 hours, the water being changed every six hours.
  • the content of the dialysis tubes then is heated under vacuum at 65° C. to yield a dry powdered basic proteinoid.
  • this powdered proteinoid spontaneously forms hollow microspheres which are stable in that environment, but which dissolve at the near neutral pH of blood.
  • microencapsulated PR-21 Dosages of the resulting suspension, in which the microspheres are predominantly 0.1 to 5 microns in diameter, are referred to below as "microencapsulated PR-21".
  • rats DA-1 and DA-2 Two rats weighing about 500 g (rats DA-1 and DA-2) are anesthetized, the jejunum is externalized and the sphincter is tied off to prevent backwash into the stomach. Two ml of microencapsulated PR-21 are then injected into the jejunum of each rat. Two similar control rats (rats DA-5 and DA-6) are similarly prepared, but are injected in the jejunum with 2 ml of unprotected PR-21. Finally, two similar control rats (rats DA-3 and DA-4) are intravenously injected with 2 ml of unprotected PR-21. Table 7 shows the amount of deacylated quaternary precursor of dopamine that is detectable in the homogenized brains of the six subjects.
  • a stirred mixture of 2 mole parts of anhydrous glutamic acid, 2 mole parts of lysine and 1 mole part of an equimolar mixture of neutral aminoacids (alanine, glycine, leucine, phenylalanine, proline, tyrosine and valine) is heated under nitrogen at 170° C. for four hours.
  • the cooled reaction product is extracted with pH 2.25 aqueous acetic acid and the extract dialyzed through a collodion membrane against distilled water for 24 hours, the water being changed every 4 hours.
  • the content of the dialysis tubes is evaporated to dryness at 65° C. under vacuum and the residual solids are ground to a fine powder.
  • this neutral powdered proteinoid spontaneously forms a profusion of hollow microspheres which encapsulate that solution or suspension.
  • microspheres are stable in human serum, but dissolve rapidly in pH 2.5 aqueous acid to release their contents. Being destabitized by exposure to reduced pH, such as that encountered when engulfed within macrophages, these neutral proteinoid microspheres are suited for the intravenous adminstration of a pharmacological agent, such as azidothymidine, which, in unprotected form, is quickly absorbed by many untargeted body tissues and cells, as well as the targeted macrophages.
  • a pharmacological agent such as azidothymidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods are described for targeting the release of an active pharmacological agent in an animal by administering that agent encapsulated in proteinoid microspheres which are stable to the environment encountered from the point of introduction until they migrate to the targeted body organs, fluids or cells and are there unstable. Orally administered delivery systems for insulin, heparin and physostigmine utilize encapsulating microspheres which are predominantly of less than about 10 microns in diameter and pass readily through the gastrointestinal mucosa and which are made of an acidic proteinoid that is stable and unaffected by stomach enzymes and acid, but which releases the microencapsulated agent in pharmacologically active form in the near neutral blood stream. Basic proteinoid microspheres encapsulating a dopamine redox carrier system are administered in the weakly basic, where they are stable, and then enter the blood stream, where the encapsulated agent is similarly released.

Description

. .This is a continuation-in-part of copending application Ser. No. 897,361, which was filed Aug. 18, 1986 and now is abandoned..!.
.Iadd.This is a continuation of application Ser. No. 07/883,562, filed May 15, 1992 now abandoned; which is a reissue of application Ser. No. 07/098,027, filed Sep. 8, 1987, now U.S. Pat. No. 4,925,673; which is a continuation-in-part of application Ser. No. 06/897,361, filed Aug. 18, 1986, now abandoned..Iaddend.
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to pharmacologically active agents which are encapsulated within protective proteinoid microspheres and the administration of same to warm blooded animals. It relates particularly to orally administered microspheres containing pharmacological agents which otherwise would be deactivated in the gastrointestinal tract.
2. Description of the Prior Art
The available modes of delivery of pharmceutical and therapeutic agents often are severely limited by chemical or physical barriers or both, which are imposed by the body. For example, oral delivery of many such agents would be the general method of choice if not for the numerous barriers faced by these agents along this route. Gastrointestinal conditions of inappropriate pH, the presence of powerful digestive enzymes, the permeability properties of gastrointestinal membranes and tissues and other factors all play important roles in determining the feasibility of oral delivery of active agents to their targets. Among the numerous pharmacological agents which are known to be adversely affected or rendered ineffective when administered orally are the biologically active polypeptides and proteins, such as insulin. These agents are rapidly destroyed in the stomach by acid hydrolysis and in the stomach and lower gastrointestinal tract by enzymes capable of cleaving peptide bonds and, in addition, they pass poorly, if at all, through the gastrointestinal wall.
A great deal of effort has been concentrated on the modification or isolation of the deleterious conditions within the gastrointestinal tract so that a pharmacological agent, which otherwise would be labile, could be absorbed through the stomach or intestine wall intact and in pharmacologically active form. The search in this area has been directed primarily in three directions; the co-administration of adjuvants, such as the resorcinols and the non-ionic surfactants polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether; the co-administration of enzymatic inhibitors, such as pancreatic trypsin inhibitor, diisopropylfluorophosphate (DFP) and trasylol; and the use of liposomes, such as water-in-oil-in-water emulsions which provide a protective layer of lipid around the encorporated pharmacological agent and which represent the most successful approach to date. For example, the use of liposomes containing heparin is disclosed in U.S. Pat. No. 4,239,754 and several studies have been directed to the use of liposomes containing insulin; e.g., Patel et al, FEBS Letters, 62, 60 (1976) and Hashimoto et al, Endocrinol. Japan, 26, 337 (1979). In spite of these demonstrations of limited operability, the use of liposomes is still in the development stage and there are continuing problems, including poor stability and inadequate shelf life.
Accordingly, there remains a need for improved means for targeting the release of active pharmacological agents in the body and particularly for more satisfactory means for oral administration of pharmacological agents which are labile to conditions in the gastrointestinal tract.
SUMMARY OF THE INVENTION
It is an object of this invention to provide improved means for releasing a pharmacological agent in physiologically active form at a targeted body organ or fluid.
It is a further object of this invention to provide an improved delivery system for the enteric administration or pharmacological agents which, by themselves, pass slowly or not at all through the gastro-intestinal mucosa and/or are susceptible to chemical cleavage by acids and enzymes in the gastrointestinal tract.
It is a specific object to provide such delivery system in which the active pharmacological agent is encapsulated within a protective material which is itself pharmacologically harmless, which does not alter the physiological and biological properties of the active agent, which protects the active agent from the deleterious conditions within the gastrointestinal tract and which disappears or releases the active agent in the bloodstream or other target. It is a further specific object of this invention to provide such combination of active agent and protective material which is sufficiently lipophilic and of small particle size to pass rapidly through the gastrointestinal mucosa and which is simple to manufacture in bulk.
Additional objects of this invention are to provide methods of producing such delivery systems and of administering same to animals. It is a specific object to provide effective means for the oral delivery of insulin to diabetic mammals.
It has been found that these objects and other advantages, which will be apparent from this specification, are achieved by the invention described below.
Broadly, one aspect of this invention is a delivery system for an active pharmacological agent comprising said agent enclosed or encapsulated within proteinoid microspheres.
A second broad aspect of this invention is a method of encapsulating an active pharmacological agent comprising mixing said active agent with a pharmaceutically acceptable liquid and contacting said mixture with a proteinoid that interacts with said mixture to form hollow microspheres.
A third broad aspect of this invention is a method for targeting the release of a pharmacologically active agent in an animal comprising administering to said animal an effective amount of said active agent encapsulated within proteinoid microspheres, said micropheres being stable to the conditions encountered during migration from the point of introduction into said animal to a targeted release zone and being unstable at said zone.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
Proteinoids, which form the protective capsules of this invention, have been described as artificial polypeptides, as they are man-made condensation polymers produced by random or directed assembly of natural or synthetic aminoacids and/or small peptide chains. Following the discovery, in the late 1950's, that linear condensation polymers of mixed natural aminoacids could interact with water to form hollow microspheres, proteinoids have been the subject of extensive investigations of the origin of life. An excellent review of these investigations, along with extensive bibliographies, is found in Fox, S. W. and Dose, K., Molecular Evolution and the Origin of Life, Marcel Dekker, Inc., New York (1977), the disclosure of which is incorporated herein by reference.
As a result of these and other studies, a great deal of knowledge has been accumulated concerning the preparation and properties of proteinoids and proteinoid microspheres. For example, it is known that proteinoids derived from the natural alpha-aminoacids (those found in animal or vegetable protein), as well as those incorporating other naturally occurring materials (such as) polynucleotides, phosphoric acid, iron and calcium), are non-toxic. It also has been found that inclusion in the polymer of a stoichiometric excess of acidic di or polycarboxylic aminoacid results in an acidic proteinoid which is insoluble in an acid environment and soluble in a basic environment, while inclusion of an excess of basic diamino or polyamino monomer results in a basic proteinoid that is soluble in an acidic medium aand insoluble at high pH. These solubility characteristics can be very finely tuned. Similarly, the size of the microspheres formed by contacting proteinoids with water or other liquid can be controlled within a range of from less that about one half micron to about ten microns or more by manipulating a variety of physical or chemical parameters, such as the pH, osmolarity or salt content of the liquid. It also has been observed that the proteinoids are far more resistant than proteins to cleavage by digestive enzymes.
The instant invention arose from the discovery that a pharmacologically active agent can be encapsulated within proteinoid microspheres simply by dissolving or suspending such agent in a pharmaceutically acceptable liquid, such as water or dimethyl sulfoxide, that interacts with that proteinoid to form microspheres.
It also has been discovered that such encapsulation does not alter the pharmacological properties of the active agent and that active agent bearing microspheres having diameters of less than about 10 microns are sufficiently small to pass readily through the gastrointestinal mucosa and enter the blood stream. The preferred range for rapid diffusion is from about 0.5 to about 5.0 microns, as smaller sizes exhibit somewhat less stability and incorporate relatively little active agent and larger sizes diffuse less readily. Particles of from about 5.0 to about 10 microns are, however, useful in admixture with those of the preferred range as their slower diffusion results in prolonged release of the active agent.
By tailoring both the solubility characteristics of an acidic proteinoid and the particle size of the microspheres by known means, it has been found to be possible to produce active agent bearing microspheres which are stable in the mouth (normal pH of from about 4 to about 6.8), which rapidly pass through the mucosa of the mouth into the bloodstream and which release the active agent in the blood (normal pH of from about 7.35 to about 7.45). Such systems are suitable for sublingual administration of pharmacological agents such as human or bovine growth hormone, interferon or interleukin-II.
Similarly, it is possible to produce readily diffusable microspheres from acidic proteinoids which are stable in the highly acidic stomach (normal pH of from about 2 to about 6), but which dissolve in the near neutral blood. Such systems are suitable for oral administration of peptide hormones, such as insulin, or heparin, which otherwise would be quickly destroyed in the stomach. They also are suitable for protecting the stomach from gastric irritants, such as aspirin. When such aspirin containing microspheres are orally administered, they pass through the gastrointestinal mucosa and release the aspirin in the bloodstream far more rapidly than conventional enterically coated aspirin, which first must traverse the stomach and then must enter the bloodstream from the intestine after the enteric coating has dissolved.
It also is possible to produce systems from basic proteinoids which are stable in the weakly basic lower digestive tract (normal pH of about 8), but which release active agent in the blood. Such systems are suitable for the administration of pharmacological agents such as calcium regulators and redox carrier systems for dopamine or gamma-aminobutyric acid.
In addition to these enterically administered delivery systems, it also is possible to produce a near neutral proteinoid microsphere system which is stable in the bloodstream, but which releases its content of pharmacological agent in response to the target organ environment, such as a higher or lower pH or the presence of a specific enzyme. Such near neutral systems must be introduced intravenously, unless the microspheres are sufficiently small to be encapsulated within larger proteinoid microspheres that are diffusible through the gastrointestinal mucosa and that are stable until they reach the bloodstream.
Although any pharmacological agent can be encapsulated within proteinoid microspheres, it obviously is of particular value for the protection of such agents which otherwise would be destroyed or rendered less effective by conditions encountered in the animal body before it reached its target zone.
Example 1, below, illustrates the preparation of an acidic thermal proteinoid that interacts with an aqueous solution of a pharmacologically active agent to encapsulate and protect that agent within hollow microspheres. These microspheres exhibit stability in the presence of the digestive enzymes and acid of the stomach and, being predominantly less thin 5.0 microns in diameter, pass readily through the gastrointestinal mucosa into the weakly basic blood stream, where they dissolve and release the pharmacological agent.
EXAMPLE 1a
A stirred mixture of 52.3 g of aspartic acid (0.4 moles), 42 g of arginine hydrochloride (0.2 moles), 26 g of isoleucine (0.2 moles) and 50 ml of glycerol is heated under nitrogen to 160° C. with the evolution of gas. The temperature then is maintained at 155° C. for 23 hours, after which the mixture is cooled to room temperature, extracted with 200 ml of 10 wt % aqueous sodium bicarbonate and the extract dialized through a collodion membrane against distilled water for 26 hours, the water being changed every six hours. The content of the dialysis tubes then is evaporated to dryness at 50° C. under vacuum to yield a glassy solid acidic proteinoid material, which is ground to a fine powder.
EXAMPLE 1b
Thirty five mg of this powdered proteinoid is added to a mixture of 50 mg of porcine insulin crystals in 2 ml of distilled water and the mixture allowed to stand at room temperature until microspheres have formed. The insulin bearing microspheres are separated by filtration, washed with pH 5.4 aqueous acetic acid and then resuspended in 2 ml of pH 5.4 aqueous acetic acid. Microscopic examination of this suspension reveals stable microspheres that are predominantly between 0.1 and 5.0 microns in diameter. When a portion of the suspension is neutralized to pH 7.4 with concentrated ammonium hydroxide, dissolution of the microspheres is immediately evident.
EXAMPLE 1c
Each of three adult white rats having normal blood glucose levels is administered a dose of 0.35 ml of the insulin bearing microsphere suspension of Example 2b by a syringe inserted through the mouth and into the stomach. Following dosage, each of these animals exhibits a significant reduction in blood glucose, as measured in blood samples taken from the tail.
Although hollow microspheres suitable for encapsulating pharmacological agents can be formed from proteinoids derived from a single acidic or basic amino acid and as few as one other amino acid, a greater diversity of component amino acids often produces higher yields of uniform size microspheres within the desirable diameter range of 0.5 to 5.0 microns. Example 2 illustrates the effectiveness, in producing a hypoglycemic effect in mammals, of the oral administration of insulin encapsulated within a proteinoid derived from 18 different amino acids.
EXAMPLE 2a
A 250 ml filter flask containing 10 g of anhydrous dl-glutamic acid and 10 g of anhydrous dl-aspartic acid under nitrogen is heated in an oil bath at approximately 200° C. until the contents are molten. To this is added 5 g of an anhydrous equimolar mixture of the sixteen neutral and basic amino acids found in animal protein; i.e., alanine, arginine, asparagine, cysteine, glycine, histadine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tyrosine, tryptophan and valine. The resulting mixture is stirred with a glass rod and maintained at 200° C. under nitrogen for three hours. After cooling, the amber product is extracted with a saturated aqueous solution of sodium bicarbonate and the resulting solution dialyzed through a collodion membrane against distilled water at room temperature for 24 hours, the water being changed every 6 hours. The content of the dialysis tubes then is acidified to pH 5.4 with concentrated acetic acid and centrifuged. After discarding the supernatant liquid, the insoluble solids are washed with pH 5.4 aqueous acetic acid and centrifuged again. This wash also is discarded and the solid proteinoid product is dried over silica gel overnight and then ground to a fine powder with mortar and pestle.
EXAMPLE 2b
A mixture of 50 mg of porcine insulin crystals in 2 ml of distilled water is added to 35 mg of the dry powdered proteinoid of Example 2a and the mixture allowed to stand at room temperature until microspheres have formed. The mixture is then centrifuged for 15 minutes. After discarding the supernatant liquid, the remaining microspheres are washed once with pH 5.4 aqueous acetic acid at room temperature and centrifuged for an additional 15 minutes. The supernatant liquid again is discarded and the insulin bearing proteinoid microspheres are resuspended in 2 ml of pH 5.4 aqueous acetic acid. Microscopic examination of the suspension shows that the microspheres are predominantly between 0.5 and 5.0 microns in diameter.
EXAMPLE 2c
Twelve male white rats, each weighing approximately 500 g and having a normal blood glucose level, are randomly assigned to four groups of three individuals for demonstrating the physiological efficacy of the oral administration of an aqueous suspension of insulin bearing proteinoid microspheres produced in accordance with the procedure of Example 2b, above. Between 0.35 and 0.5 ml of this aqueous suspension of microspheres is administered by gavage into the stomach of each rat in Group One. The Group Two rats have between 1.5 and 1.7 ml of the suspension similarly administered. The rats of Group Three receive 1.0 ml of distilled water similarly administered. The rats of Group Four similarly receive 25.0 mg of porcine insulin in 1.0 ml of distilled water. Both before and during the experiment, all animals are permitted free access to water and their normal feed. Blood glucose levels are measured on samples drawn from the tail at specific intervals after treatment and group averages are recorded in Table 1 as milligrams of glucose per deciliter of blood (mg/dl).
              TABLE 1                                                     
______________________________________                                    
Ave. Blood Glucose (mg/dl)                                                
______________________________________                                    
Group Predose 30 min. 1 hr. 1.5 hr.                                       
                                  2 hr. 2.5 hr                            
                                              3 hr.                       
______________________________________                                    
One   135      85      88    66    44    27   --                          
Two   --      --      --    --    --     49   --                          
Three 120     --      --    --    --    119   --                          
Four  113     120     120   124   120   --    116                         
______________________________________                                    
Group 4 hr.   6 hr.   12 hr.                                              
                            24 hr.                                        
                                  36 hr.                                  
                                        48 hr.                            
______________________________________                                    
One    38     --      135   119   122   --                                
Two    58     --       80   125   125   122                               
Three 122     --      --    119   124   --                                
Four  111     123     --    --    --    --                                
______________________________________
It is clear from the data in Table 1 that insulin is delivered in a physiologically meaningful and active fashion via the oral route with acidic proteinoid microspheres. In all animals receiving insulin containing microspheres, the blood glucose level returns to the pre-administration level without any observed adverse effect. It should be noted that the administration of larger doses of insulin containing microspheres to the Group Two animals appears to increase the duration of action rather than the magnitude of the effect. It also should be noted that the oral administration of far larger dosages per unit of body weight of unprotected porcine or bovine insulin to laboratory animals and humans produces no detectable reduction of blood glucose levels.
Similarly effective insulin bearing proteinoid microspheres can be produced by contacting a dry powered acidic proteinoid, such as those of Examples 1a or 2a, with insulin suspended or dissolved in a wide variety of pharmaceutically acceptable liquids, including aqueous solutions of ethanol, isopropanol, terpenol, dimethyl sulfoxide, starch, Tweens 80 and cyclodextran.
Example 3 illustrates an especially preferred method of producing insulin bearing proteinoid microspheres which reliably produces high yields of microspheres that fall within the desirable diameter range of 0.5 to 5.0 microns and that are readily soluble at the pH of the targeted blood.
EXAMPLE 3a
A flask containing 2 parts by weight or anhydrous 1-glutamic acid under a stream of nitrogen is heated in an oil bath at approximately 175° C. until the contents are molten. To this is added 2 parts by weight of anhydrous 1-aspartic acid and one part by weight of an anhydrous equimolar mixture of the sixteen neutral and basic amino acids found in animal protein. The resulting mixture is stirred with a glass rod and maintained at 175° C. under nitrogen for three hours. After cooling, the dark amber product is extracted with saturated aqueous sodium bicarbonate and the extract dialyzed through a collodion membrane against distilled water at room temperature for 24 hours, the water being changed every four hours. The entire content of the dialysis tubes then is dried under vacuum at 65° and the residual solids are ground to a fine powder with mortar and pestle.
EXAMPLE 3b
An aqueous solution of proteinoid is produced by mixing 35 mg of the powder of Example 3a per ml of water, adjusting the pH to 7.4 with concentrated aqueous sodium bicarbonate and removing any insoluble materials by filtration. One part by volume of this solids free solution of proteinoid then is rapidly injected into an equal volume of a freshly prepared 25 mg/ml solution of porcine insulin in pH 2.25 aqueous acetic acid. The mixture, which has a pH of approximately 3.5, is stirred in an ice bath for 15 minutes and filtered to separate the insulin bearing microspheres from the filtrate which is discarded. After washing twice with pH 3.5 aqueous acetic acid, the microspheres are resuspended in 10 parts by volume of pH 3.5 aqueous acetic acid. Microscopic examination of a portion of this suspension shows a high yield of microspheres which are predominantly between 0.5 and 5.0 microns in diameter and which dissolve rapidly when the suspension is neutralized to pH 7.4 by the addition of concentrated aqueous sodium bicarbonate.
In the following Example 4, dosages of the insulin bearing microsphere suspension of Example 3b are referred to as "insulin filled microspheres". Microspheres which contain no encapsulated insulin are produced by repeating the procedure of Example 3b, except that the insulin is omitted during the formation of microspheres and the microspheres are suspended in a 2.5 mg/ml solution of porcine insulin in distilled water, rather than in dilute acetic acid. Doses of the resulting suspension, which contain no insulin within the microspheres, are referred to as "microspheres with external insulin". Dosages of the 2.5 mg/ml solution of porcine insulin alone are referred to as "raw insulin".
EXAMPLE 4
Twelve male white rats, each weighing approximately 500 g and havinng a normal blood glucose level, are arbitrarily assigned to two groups of three animals and a third group of six animals. The three animals of group A are administered the insulin filled microspheres by gavage and the three animals of group B are similarly administered the microspheres with external insulin. The six animals of group C similarly receive the raw insulin. All dosages are 1 ml/500 g of body weight and all animals are tested for blood glucose immediately before dosage and at intervals thereafter. The average blood glucose level for the animals in each group is shown in Table 2.
              TABLE 2                                                     
______________________________________                                    
Blood Glucose (mg/dl) in Rats                                             
Group Treatment                                                           
      A            B                                                      
Time  (Insulin Filled                                                     
                   (Microspheres with                                     
                                 C                                        
(hrs) Microspheres)                                                       
                   External Insulin)                                      
                                 (Raw Insulin)                            
______________________________________                                    
0     109.7        92            92.7                                     
.5    54.7         89.3          95.5                                     
1     59           84.3          98.2                                     
2     50           80.7          95.8                                     
3     57.7         86.7          86.2                                     
4     64.7         84            91                                       
6     76           83.7          89.8                                     
8     65.7         88.7          91                                       
12    81.7         92.3          92                                       
24    94.3         95.7          92                                       
______________________________________
These experiments show no significant effect on blood glucose levels of either the raw insulin or the microspheres with external insulin. In contrast, the insulin filled microspheres produce a peak reduction of approximately 50% and an effect of long duration. This demonstrates that the acidic proteinoid microspheres have no effect on blood glucose levels and that they protect only the encapsulated insulin from the hostile environment of the stomach, thereby enabling that encapsulated insulin to enter the blood stream in physiologically active form.
EXAMPLE 5a
Diabetes mellitis is induced in rats weighing approximately 300 g by giving each a 75 mg/kg body weight intravenous injection of streptozotocin. Ten rats which are observed to show consistently high blood glucose levels, polyuria and polydipsia and must be maintained on subcutaneous injections of porcine insulin are selected for this experiment.
EXAMPLE 5b
Three of the diabetic rats are administered by gavage approximately 1 ml of the aqueous suspension of porcine insulin bearing acidic proteinoid microspheres of Example 3b. A fourth diabetic rat has 3 ml of the suspension in 50 ml of tap water placed in its water bottle and this rat self administers his dose. All of the rats are food deprived for 12 hours prior to dosing. In all subjects, the oral administration of the microencapsulated insulin produces a significant and prolonged reduction in blood glucose levels.
EXAMPLE 5c
The remaining six diabetic rats are arbitrarily assigned to three groups of two animals. The animals of the first group are administered by gavage 1 ml of the aqueous suspension of porcine insulin bearing acidic proteinoid microspheres of Example 3b. The animals of the second and third groups receive subcutaneous injections of 0.25 mg (6.5 I.U.) and 0.125 mg (3.25 I.U.), respectively, of porcine insulin. Blood glucose measurements are made on all animals immediately before dosing and at intervals thereafter. The animal groups are crossed over twice at one week intervals, so that all of the animals receive each of the insulin treatments. The average percent decrease from baseline blood glucose levels for each treatment is shown in Table 3.
              TABLE 3                                                     
______________________________________                                    
% Decrease from Baseline Blood Glucose in Rats                            
        Time (hrs.) after Dosage                                          
Insulin Treatment                                                         
          0.5   1     1.5 2   3   4   6   8   12  24  48                  
______________________________________                                    
Microspheres                                                              
          29    38    45  44  48  50  51  40  37  24  -27                 
Oral                                                                      
0.25 mg SC                                                                
          28    55    72  77  84  79  34  4   3   -7  -5                  
0.125 mg SC                                                               
          5     17    27  45  47  29  8   -8  -8  -8  -8                  
______________________________________
These results demonstrate that the peak effect of the orally administered dose of insulin filled microspheres on diabetic rats is comparable to a subcutaneous injection of 0.125 mg of insulin and that the duration of the effect is significantly longer than that produced by either a 0.125 mg or a 0.25 mg subcutaneous injection.
EXAMPLE 6
One ml of the aqueous suspension of porcine insulin bearing acidic proteinoid microspheres of Example 3b is administered by gavage into the stomach of each of three adult guinea pigs weighing approximately 800 g. Blood samples are taken immediately before and at intervals after administration of the dosage.
The blood samples from guinea pig #1 are tested for blood glucose, which drops from a predosage level of 160 mg/dl to 42 mg/dl in one half hour and to 25 mg/dl in 1.5 hours, where it remains for an additional 1.5 hours, at which time symptoms of insulin shock are observed and the animal is revived by orally administered glucose.
The blood samples from guinea pigs #2 and #3 are tested for porcine insulin with radioimmuno assay kits, which are marketed by Cambridge Medical Diagnostics. This method, which distinguishes between porcine and guinea pig insulin, shows that the predosage level of porcine insulin in the blood of both guinea pigs #2 and #3 is zero. In guinea pig #2 the concentration peaks at 250 micrograms/ml one and one half hours after oral administration of the microspheres and in guinea pig #3 a peak of 240 micrograms/ml is reached in four hours.
These experiments demonstrate that the orally administered porcine insulin has a powerful hypoglycemic effect in a guinea pig, that it actually enters the blood stream and that its administration does not merely stimulate guinea pig insulin production by the animal.
EXAMPLE 7a
The procedure of Example 3b is repeated, except that the insulin filled microspheres are suspended in aqueous acetic acid having a pH of 2.25, rather than 3.5. A sealed vial of this suspension is stored at room temperature for 23 days.
EXAMPLE 7b
The activity of the thus aged encapsulated insulin is tested by administering the suspension by gavage to the stomachs of adult rats which have been deprived of rood for eight hours and then measuring blood glucose levels at intervals after dosage. The results are shown in Table 4.
              TABLE 4                                                     
______________________________________                                    
Blood Glucose (mg/dl)                                                     
             Time after Dosage (hrs.)                                     
Rat #                                                                     
     weight (g)                                                           
              dose (ml)                                                   
                       0    0.5  1.0  1.5  2.0  3.0                       
______________________________________                                    
40   398      0.40     64   49   44   34   33   35                        
41   415      0.42     79   89   35   82   80   80                        
42   479      0.48     79   50   34   37   37   49                        
______________________________________
Normally insulin in solution can be expected to degrade within a few days, even when refrigerated. The magnitude of the blood sugar reduction in all of thes rats and the prolonged effect shown by rats #40 and 42 indicate that insulin solution stability is improved by encapsulation within acidic proteinoid microspheres.
EXAMPLE 7c
The aged suspension of encapsulated insulin is added to human serum and, employing a standard laboratory haemocytometer counting technique, the number of microspheres are counted immediately after mixing and at intervals thereafter. Table 5 shows the number of microspheres observable as a function of time.
              TABLE 5                                                     
______________________________________                                    
Dissolution of Microspheres in Human Serum                                
______________________________________                                    
Time (minutes)   0     3         30  60                                   
Microspheres (× 1000)                                               
                 78    50        19  9                                    
______________________________________
This data demonstrates that insulin bearing acidic proteinoid microspheres which have remained intact after 23 days exposure at room temperature to pH 2.25 aqueous acetic acid still dissolve rapidly in near neutral human serum.
EXAMPLE 8a
An aqueous solution of heparin containing 250 mg/ml of heparin is adjusted to pH 4.5 by the addition of concentrated acetic acid. To this is added 35 mg/ml of the dry powdered acidic proteinoid of Example 3a and the mixture is allowed to stand at room temperature until microspheres have formed. One part by volume of the mixture then is centrifuged and, after discarding the supernatant liquid, the heparin bearing microspheres are washed with pH 4.5 aqueous acetic acid, filtered and resuspended in pH 4.5 aqueous acetic acid, the suspension being made up to one part by volume. Microscopic examination reveals that the microspheres are predominantly within the range of from about 0.1 to about 5 microns in diameter, with the majority being between 1 and 2 microns.
EXAMPLE 8b
Seven male white rats, each weighing approximately 600 g, are deprived of food for 12 hours before the start of the experiment. Rat #1 receives no treatment. Rat #2 receives an intravenous injection of 250 mg of heparin in one ml of distilled water. Each of rats #3-7 has 1 ml of the aqueous suspension of heparin bearing microspheres of Example 8a introduced directly into the stomach by gavage. The effect of heparin is determined using the Activated Partial Thromboplastin Time (APTT) test. This test measures the time necessary for a sample of serum taken from the tail vein to form a fibrin clot. The results for each rat at various times after dosing are shown in Table 6.
              TABLE 6                                                     
______________________________________                                    
Time to Coagulation in the APTT Test (seconds)                            
     Heparin                                                              
Rat #                                                                     
     Treatment Predose 1 hr. 2 hrs.                                       
                                  3 hrs.                                  
                                        4 hrs.                            
                                             24 hrs.                      
______________________________________                                    
1    none      28      26    27   --    --   --                           
2    IV        25      54    >300 --    --   --                           
3    microspheres                                                         
               24      35    >300 --    --   --                           
4    "         26      35    59   118   >300 21                           
5    "         29      41    63   106   248  26                           
6    "         25      37    66   121   >300 23                           
7    "         24      31    62   111   >300 37                           
______________________________________
In all animals receiving heparin bearing microspheres, coagulation time increases to a level comparable to that seen following an intravenous injection of heparin. It is clear from this data that heparin is delivered to the bloodstream in a physiologically meaningful and active fashion when encapsulated in acidic proteinoid microspheres and administered orally. It should be noted that the oral administration of far larger doses per unit of body weight of unprotected heparin to laboratory animals and humans produces no detectable increase in coagulation time.
EXAMPLE 9a
An aqueous solution of physostigmine containing 50 mg/ml of physostigmine is adjusted to pH 5 by the addition of concentrated acetic acid. To one volume of this solution is added 100 mg per ml of the dry powdered acidic proteinoid of Example 3a and the mixture is allowed to stand at room temperature until microspheres have formed. It then is filtered, washed three times with pH 5 aqueous acetic acid and the separated microspheres are resuspended in one volume of pH 5 acetic acid. Microscopic examination reveals that the suspended microspheres are predominantly 0.5-5.0 microns in diameter.
EXAMPLE 9b
Each of two normal rats weighing about 360 g is administered by gavage 3 ml of the suspension of physostigmine bearing microspheres. Within 30 minutes of dosage, both animals have died and each exhibits enlarged liver and peritoneal hemorrhage. These lethal oral dosages of microencapsulated physostigmine are calculated to be less than one percent of the LD50 oral dosage of unprotected physostigmine in rats.
In addition to the specific pharmacological agents that are shown by the above examples to be released in the blood stream in physiologically active form when orally administered within protective acidic proteinoid microspheres, such microsphere delivery system is similarly effective with a wide variety of other agents which are labile in the stomach invironment, including nitroglycerin, Salk polio vaccine, rubella vaccine and hepatitis B vaccine. There are, however many other pharmacological agents which could be deleteriously affected by even the mildly acidic conditions encountered during encapsulation within acidic proteinoid microspheres.
The following experiment demonstrates the ability of a basic proteinoid to form microspheres which encapsulate and protect one such extremely acid sensitive pharmacological agent, a dopamine derivative, from the hostile environment of the gastrointestinal tract, as well as to deliver that agent to the circulatory system, from which it penetrates the brain blood barrier and releases dopamine in the brain. The dopamine derivative employed in this experiment is PR-21, which is a proprietary composition of acylated dopamine bonded to a reduced dihydropyridine/pyridinium salt type redox carrier which was developed by Pharmatek, Inc. and is described in U.S. Pat. No. 4,479,932. The unprotected PR-21 composition is unstable anywhere in the gastrointestinal tract and is particularly sensitive to acid conditions. When injected intravenously into rats, significant amounts of the deacylated quaternary precursor of dopamine can be measured in the homogenized rat brain by the method of Bodir and Farog, Journal of Medicinal Chemistry, 26, 528 (1983).
EXAMPLE 10a
A nitrogen swept mixture of two parts by weight of arginine, two parts by weight of lysine and one part by weight of an equimolar mixture of the sixteen neutral and acidic aminoacids found in animal protein is stirred and heated at 180° C. for 3 hours. The cooled reaction mixture is extracted with pH 2.25 aqueous acetic acid and the extract is dialyzed through a collodion membrane against a large volume of distilled water at room temperature for 48 hours, the water being changed every six hours. The content of the dialysis tubes then is heated under vacuum at 65° C. to yield a dry powdered basic proteinoid. When suspended in a moderate to strongly alkaline liquid environment, this powdered proteinoid spontaneously forms hollow microspheres which are stable in that environment, but which dissolve at the near neutral pH of blood.
EXAMPLE 10b
One part by volume of an ethanol solution of PR-21 (360 mg/ml) is diluted with an equal volume of distilled water and the pH of the solution is adjusted to 8 by the addition of saturated aqueous monobasic potassium phosphate buffer. A portion of this buffered solution, which contains 180 mg/ml of PR-21, is set aside and dosages of it are referred to below as "unprotected PR-21".
The remainder of the buffered solution is mixed with 25 mg/ml of the dry powdered basic proteinoid of Example 10a and chilled in an ice bath until microspheres have formed. Dosages of the resulting suspension, in which the microspheres are predominantly 0.1 to 5 microns in diameter, are referred to below as "microencapsulated PR-21".
EXAMPLE 10c
Two rats weighing about 500 g (rats DA-1 and DA-2) are anesthetized, the jejunum is externalized and the sphincter is tied off to prevent backwash into the stomach. Two ml of microencapsulated PR-21 are then injected into the jejunum of each rat. Two similar control rats (rats DA-5 and DA-6) are similarly prepared, but are injected in the jejunum with 2 ml of unprotected PR-21. Finally, two similar control rats (rats DA-3 and DA-4) are intravenously injected with 2 ml of unprotected PR-21. Table 7 shows the amount of deacylated quaternary precursor of dopamine that is detectable in the homogenized brains of the six subjects.
              TABLE 7                                                     
______________________________________                                    
Dopamine Quaternary Precursor in Rat Brains                               
Rat #   Treatment       Precursor (micrograms/g)                          
______________________________________                                    
DA-1    Intestinal Injection,                                             
                        1                                                 
        Microencapsulated PR-21                                           
DA-2    Intestinal Injection,                                             
                        10                                                
        Microencapsulated PR-21                                           
DA-3    IV Injection,   3                                                 
        Unprotected PR-21                                                 
DA-4    IV Injection,   4.5                                               
        Unprotected PR-21                                                 
DA-5    Intestinal Injection,                                             
                        0                                                 
        Unprotected PR-21                                                 
DA-6    Intestinal Injection,                                             
                        0                                                 
        Unprotected PR-21                                                 
______________________________________
These results demonstrate the capacity of basic proteinoid microspheres to encapsulate and protect a dopamine derivative from the digestive enzymes and basic environment of the intestine, as well as the fact that such microspheres are transported across the gastrointestinal mucosa into the rear neutral blood stream where the encapsulated dopamine derivative is released. For successful oral delivery of such encapsulated pharmacological agent, the acid sensitive basic proteinoid microspheres must be protected while traversing the mouth and stomach. Advantageously, this is accomplished by a conventional enteric coating which does not dissolve until it reaches the intestine.
EXAMPLE 11
A stirred mixture of 2 mole parts of anhydrous glutamic acid, 2 mole parts of lysine and 1 mole part of an equimolar mixture of neutral aminoacids (alanine, glycine, leucine, phenylalanine, proline, tyrosine and valine) is heated under nitrogen at 170° C. for four hours. The cooled reaction product is extracted with pH 2.25 aqueous acetic acid and the extract dialyzed through a collodion membrane against distilled water for 24 hours, the water being changed every 4 hours. The content of the dialysis tubes is evaporated to dryness at 65° C. under vacuum and the residual solids are ground to a fine powder. When added to a pH 7.4 aqueous solution or suspension of a pharmacological agent, this neutral powdered proteinoid spontaneously forms a profusion of hollow microspheres which encapsulate that solution or suspension.
These microspheres are stable in human serum, but dissolve rapidly in pH 2.5 aqueous acid to release their contents. Being destabitized by exposure to reduced pH, such as that encountered when engulfed within macrophages, these neutral proteinoid microspheres are suited for the intravenous adminstration of a pharmacological agent, such as azidothymidine, which, in unprotected form, is quickly absorbed by many untargeted body tissues and cells, as well as the targeted macrophages.
It will be apparent to those of ordinary skill in the art that numerous changes and modifications can be made in the illustrative embodiments of the invention described above without departing from the spirit or scope of the invention as set forth in the following claims.

Claims (28)

We claim:
1. Composition comprising a pharmacologically active agent encapsulated within protenoid microspheres having diameters predominantly less than about 10 microns and formed from linear thermal condensation polymers of mixed amino acids.
2. Composition of claim 1 wherein said microspheres are stable in at least a segment of the gastrointestinal tract, are unstable in the blood stream and are predominatly less than about 10 microns in diameter so as to readily penetrate the gastrointestinal mucosa and release said active agent in the blood stream in physiologically active form.
3. Composition of claim 2 wherein said polymer is acidic and said microspheres are stable to acids and enzymes in the mouth.
4. Composition of claim 2 wherein said polymer is basic and said microspheres are stable in the weakly basic lower digestive tract.
5. Composition of claim 4 wherein said pharmacological agent is a dopamine redox carrier system.
6. Composition of claim 2 wherein said polymer is acidic and said microspheres are stable to acids and enzymes in the stomach.
7. Composition of claim 6 wherein said pharmacological agent is insulin.
8. Composition of claim 6 wherein said pharmacological agent is heparin.
9. Composition of claim 6 wherein said pharmacological agent is physostigmine.
10. Composition of claim 1 wherein said polymer is neutral and said microspheres are stable in the blood stream and are unstable at reduced pH.
11. Composition of claim 1 wherein said microspheres are predominantly from about 0.5 to about 5.0 microns in diameter.
12. Method for microencapsulating a pharmacologically active agent within microspheres for targeted release within a selected pH range comprising forming a mixture of said agent with a pharmaceutically acceptable liquid, said mixture having a pH outside said selected range, and contacting said mixture with proteinoids formed of linear thermal condensation polymers of mixed amino acids which are soluble within said selected pH range and insoluble in said mixture to form microspheres having diameters predominately less than about 10 microns containing the active agent.
13. Method of claim 12 wherein said pharmaceutically acceptable liquid is water.
14. Method of claim 12 including preliminary purification of said polymers by mixing the polymers with water having a pH within said selected range and separating the resulting aqueous solution of said polymers from any insoluble material.
15. Method for producing an orally administerable composition for delivering insulin to the blood stream in physiologically active form comprising mixing insulin with water and contacting said mixture with a thermal condensation polymer derived from about two parts glutamic acid, about two parts aspartic acid and about one part of neutral or basic alpha-aminoacid.
16. Method for targeting release of a pharmacologically active agent in an animal comprising administering to said animal an effective amount of said active agent encapsulated within proteinoid microspheres formed from linear thermal condensation polymers of mixed amino acids having diameters predominately less than about 10 microns, said microspheres being stable to the conditions encountered during migration from the point of introduction into said animal to a targeted release zone and being unstable at said zone.
17. Method of claim 16 wherein said microspheres are predominantly from about 0.5 to about 5.0 microns in diameter.
18. Method of claim 16 wherein said microspheres are enterically administered for targeted release in the blood stream and said microspheres are stable in that segment of the gastrointestinal tract into which they are introduced and are unstable in the blood stream.
19. Method of claim 18 wherein said encapsulated active agent is sublingually introduced into the bloodstream and said microspheres are sufficiently acidic to be stable at a pH of from about 4 to about 6.8 and unstable at a pH of from about 7.35 to about 7.45.
20. Method of claim 18 wherein said encapsulated active agent is introduced into the bloodstream from the weakly basic lower gastrointestinal tract and said microspheres are sufficiently basic to be stable at a pH of about 8 and unstable at a pH of from about 7.35 to about 7.45.
21. Method of claim 18 wherein said encapsulated active agent is gastrically introduced into the bloodstream and said microspheres are sufficiently acidic to be stable at a pH of from about 2 to about 6 and unstable at a pH of from about 7.35 to about 7.45.
22. Method of claim 16 wherein said microspheres are intravenously administered and are stable at a pH of from about 7.35 to about 7.45 and unstable at reduced pH.
23. Method of treating a diabetic conditions in an animal comprising orally administering to said animal an effective amount of insulin which is encapsulated within acidic protenoid microspheres formed from linear thermal condensation polymers of mixed amino acids, said microspheres being predominantly from about 0.5 to about 5.0 microns in diameter, stable at a pH of up to about 6 and unstable at a pH of from about 7.35 to about 7.45. .Iadd.
24. Composition comprising a pharmacologically active agent encapsulated within proteinoid microspheres having diameters predominantly less than about 10 microns and formed from thermal condensation polymers of mixed amino acids..Iaddend..Iadd.25. Method for microencapsulating a pharmacologically active agent within microspheres for targeted release within a selected pH range comprising forming a mixture of said agent with a pharmaceutically acceptable liquid, said mixture having a pH outside said selected range, and contacting said mixture with proteinoids formed of thermal condensation polymers of mixed amino acids which are soluble within said selected pH range and insoluble in said mixture to form microspheres having diameters predominantly less than about 10 microns containing the active agent..Iaddend..Iadd.26. Method for targeting release of a pharmacologically active agent in an animal comprising administering to said animal an effective amount of said active agent encapsulated within proteinoid microspheres formed from thermal condensation polymers of mixed amno acids having diameters predominately less than about 10 microns, said microspheres being stable to the conditions encountered during migration from the point of introduction into said animal to a targeted release zone and being unstable at said
zone..Iaddend..Iadd.27. Method of treating diabetic conditions in an animal comprising orally administering to said animal an effective amount of insulin which is encapsulated within acidic proteinoid microspheres formed from thermal condensation polymers of mixed amino acids, said microspheres being predominantly from about 0.5 to about 5.0 microns in diameter, stable at a pH of up to about 6 and unstable at a pH of from about 7.35 to about 7.45..Iaddend..Iadd.28. Composition comprising a pharmacologically active agent encapsulated within proteinoid microspheres having diameters predominantly less than about 10 microns and formed from condensation polymers of mixed amino acids..Iaddend..Iadd.29. Method for microencapsulating a pharmacologically active agent within microspheres for targeted release within a selected pH range comprising forming a mixture of said agent with a pharmaceutically acceptable liquid, said mixture having a pH outside said selected range, and contacting said mixture with proteinoids formed of condensation polymers of mixed amino acids which are soluble within said selected pH range and insoluble in said mixture to form microspheres having diameters predominantly less than about 10 microns containing the active agent..Iaddend..Iadd.30. Method for targeting release of a pharmacologically active agent in an animal comprising administering to said animal an effective amount of said active agent encapsulated within proteinoid microspheres formed from condensation polymers of mixed amino acids having diameters predominately less than about 10 microns, said microspheres being stable to the conditions encountered during migration from the point of introduction into said animal to a targeted release zone and being unstable at said zone..Iaddend..Iadd.31. Method of treating diabetic conditions in an animal comprising orally administering to said animal an effective amount of insulin which is encapsulated within acidic proteinoid microspheres formed from condensation polymers of mixed amino acids, said microspheres being predominantly from about 0.5 to about 5.0 microns in diameter, stable at a pH of up to about 6 and unstable at a pH of from about 7.35 to about 7.45..Iaddend..Iadd.32. Composition comprising a pharmacologically active agent encapsulated within proteinoid microspheres having diameters predominantly less than about 10 microns and formed from polymers of mixed amino acids..Iaddend..Iadd.33. Method for microencapsulating a pharmacologically active agent within microspheres for targeted release within a selected pH range comprising forming a mixture of said agent with a pharmaceutically acceptable liquid, said mixture having a pH outside said selected range, and contacting said mixture with proteinoids formed of polymers of mixed amino acids which are soluble within said selected pH range and insoluble in said mixture to form microspheres having diameters predominantly less than about 10 microns containing the active agent..Iaddend..Iadd.34. Method for targeting release of a pharmacologically active agent in an animal comprising administering to said animal an effective amount of said active agent encapsulated within proteinoid microspheres formed from polymers of mixed amino acids having diameters predominately less than about 10 microns, said microspheres being stable to the conditions encountered during migration from the point of introduction into said animal to a targeted release zone and being unstable at said zone..Iaddend..Iadd.35. Method of treating diabetic conditions in an animal comprising orally administering to said animal an effective amount of insulin which is encapsulated within acidic proteinoid microspheres formed from polymers of mixed amino acids, said microspheres being predominantly from about 0.5 to about 5.0 microns in diameter, stable at a pH of up to about 6 and unstable at a pH of from about 7.35 to about 7.45..Iaddend..Iadd.36. Composition comprising a pharmacologically active agent encapsulated within proteinoid microspheres having diameters predominantly less than about 10 microns and formed from mixed amino
acids..Iaddend..Iadd.37. Method for microencapsulating a pharmacologically active agent within microspheres for targeted release within a selected pH range comprising forming a mixture of said agent with a pharmaceutically acceptable liquid, said mixture having a pH outside said selected range, and contacting said mixture with proteinoids formed of mixed amino acids which are soluble within said selected pH range and insoluble in said mixture to form microspheres having diameters predominantly less than about 10 microns containing the active agent..Iaddend..Iadd.38. Method for targeting release of a pharmaceutically active agent in an animal comprising administering to said animal an effective amount of said active agent encapsulated within proteinoid microspheres formed from mixed amino acids having diameters predominately less than about 10 microns, said microspheres being stable to the conditions encountered during migration from the point of introduction into said animal to a targeted release zone and being unstable at said zone..Iaddend..Iadd.39. Method of treating diabetic conditions in an animal comprising orally administering to said animal an effective amount of insulin which is encapsulated within acidic proteinoid microspheres formed from mixed amino acids, said microspheres being predominantly from about 0.5 t about 5.0 microns in diameter, stable at a pH of up to about 6 and unstable at a pH of from about 7.35 to about
7.45..Iaddend..Iadd.40. Composition comprising a pharmacologically active agent encapsulated within proteinoid microspheres having diameters predominantly less than about 10 microns and formed from directed polymers of mixed amino acids..Iaddend..Iadd.41. Method for microencapsulating a pharmacologically active agent within microspheres for targeted release within a selected pH range comprising forming a mixture of said agent with a pharmaceutically acceptable liquid, said mixture having a pH outside said selected range, and contacting said mixture with proteinoids formed of directed polymers of mixed amino acids which are soluble within said selected pH range and insoluble in said mixture to form microspheres having diameters predominantly less than about 10 microns containing the active agent..Iaddend..Iadd.42. Method for targeting release of a pharmacologically active agent in an animal comprising administering to said animal an effective amount of said active agent encapsulated within proteinoid microspheres formed from directed polymers of mixed amino acids having diameters predominately less than about 10 microns, said microspheres being stable to the conditions encountered during migration from the point of introduction into said animal to a targeted release zone and being unstable at said zone..Iaddend..Iadd.43. Method of treating diabetic conditions in an animal comprising orally administering to said animal an effective amount of insulin which is encapsulated within acidic proteinoid microspheres formed from directed polymers of mixed amino acids, said microspheres being predominantly from about 0.5 to about 5.0 microns in diameter, stable at a pH of up to about 6 and unstable at a pH of from about 7.35 to about 7.45..Iaddend..Iadd.44. Composition comprising a pharmacologically active agent encapsulated within proteinoid microspheres having diameters predominantly less than about 10 microns and formed from directed condensation polymers of mixed amino acids..Iaddend..Iadd.45. Method for microencapsulating a pharmacologically active agent within microspheres for targeted release within a selected pH range comprising forming a mixture of said agent with a pharmaceutically acceptable liquid, said mixture having a pH outside said selected range, and contacting said mixture with proteinoids formed of directed condensation polymers of mixed amino acids which are soluble within said selected pH range and insoluble in said mixture to form microspheres having diameters predominantly less than about 10 microns containing the active agent..Iaddend..Iadd.46. Method for targeting release of a pharmacologically active agent in an animal comprising administering to said animal an effective amount of said active agent encapsulated within proteinoid microspheres formed from directed condensation polymers of mixed amino acids having diameters predominately less than about 10 microns, said microspheres being stable to the conditions encountered during migration from the point of introduction into said animal to a targeted release zone and being unstable at said zone..Iaddend..Iadd.47. Method of treating diabetic conditions in an animal comprising orally administering to said animal an effective amount of insulin which is encapsulated within acidic proteinoid microspheres formed from directed condensation polymers of mixed amino acids, said microspheres being predominantly from about 0.5 to about 5.0 microns in diameter, stable at a pH of up to about 6 and unstable at a pH of from about 7.35 to about 7.45..Iaddend..Iadd.48. Composition comprising a pharmacologically active agent encapsulated within proteinoid microspheres having diameters predominantly less than about 10 microns and formed from random polymers of mixed amino acids..Iaddend..Iadd.49. Method for microencapsulating a pharmacologically active agent within microspheres for targeted release within a selected pH range comprising forming a mixture of said agent with a pharmaceutically acceptable liquid, said mixture having a pH outside said selected range, and contacting said mixture with proteinoids formed of random polymers of mixed amino acids which are soluble within said selected pH range and insoluble in said mixture to form microspheres having diameters predominantly less than about 10 microns containing the active agent..Iaddend..Iadd.50. Method for targeting release of a pharmacologically active agent in an animal comprising administering to said animal an effective amount of said active agent encapsulated within proteinoid microspheres formed from random polymers of mixed amino acids having diameters predominately less than about 10 microns, said microspheres being stable to the conditions encountered during migration from the point of introduction into said animal to a targeted release zone and being unstable at said zone..Iaddend..Iadd.51. Method of treating diabetic conditions in an animal comprising orally administering to said animal an effective amount of insulin which is encapsulated within acidic proteinoid microspheres formed from random polymers of mixed amino acids, said microspheres being predominantly from about 0.5 to about 5.0 microns in diameter, stable at a pH of up to about 6 and unstable at a pH of from about 7.35 to about 7.45..Iaddend..Iadd.52. Composition comprising a pharmacologically active agent encapsulated within proteinoid microspheres having diameters predominantly less than about 10 microns and formed from
random condensation polymers of mixed amino acids..Iaddend..Iadd.53. Method for microencapsulating a pharmacologically active agent within microspheres for targeted release within a selected pH range comprising forming a mixture of said agent with a pharmaceutically acceptable liquid, said mixture having a pH outside said selected range, and contacting said mixture with proteinoids formed of random condensation polymers of mixed amino acids which are soluble within said selected pH range and insoluble in said mixture to form microspheres having diameters predominantly less than about 10 microns containing the active agent..Iaddend..Iadd.54. Method for targeting release of a pharmacologically active agent in an animal comprising administering to said animal an effective amount of said active agent encapsulated within proteinoid microspheres formed from random condensation polymers of mixed amino acids having diameters predominately less than about 10 microns, said microspheres being stable to the conditions encountered during migration from the point of introduction into said animal to a targeted release zone and being unstable at said zone..Iaddend..Iadd.55. Method of treating diabetic conditions in an animal comprising orally administering to said animal an effective amount of insulin which is encapsulated within acidic proteinoid microspheres formed from random condensation polymers of mixed amino acids, said microspheres being predominantly from about 0.5 to about 5.0 microns in diameter, stable at a pH of up to about 6 and unstable at a pH of from about 7.35 to about 7.45..Iaddend.
US08/252,979 1986-08-18 1987-08-14 Delivery systems for pharmacological agents encapsulated with proteinoids Expired - Lifetime USRE35862E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/252,979 USRE35862E (en) 1986-08-18 1987-08-14 Delivery systems for pharmacological agents encapsulated with proteinoids

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89736186A 1986-08-18 1986-08-18
US07/098,027 US4925673A (en) 1986-08-18 1987-08-14 Delivery systems for pharmacological agents encapsulated with proteinoids
US08/252,979 USRE35862E (en) 1986-08-18 1987-08-14 Delivery systems for pharmacological agents encapsulated with proteinoids
PCT/US1987/002025 WO1988001213A1 (en) 1986-08-18 1987-08-14 Delivery systems for pharmacological agents
US88356292A 1992-05-15 1992-05-15

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US07/098,027 Reissue US4925673A (en) 1986-08-18 1987-08-14 Delivery systems for pharmacological agents encapsulated with proteinoids
US88356292A Continuation 1986-08-18 1992-05-15

Publications (1)

Publication Number Publication Date
USRE35862E true USRE35862E (en) 1998-07-28

Family

ID=27378488

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/252,979 Expired - Lifetime USRE35862E (en) 1986-08-18 1987-08-14 Delivery systems for pharmacological agents encapsulated with proteinoids

Country Status (1)

Country Link
US (1) USRE35862E (en)

Cited By (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
WO2001051454A1 (en) 2000-01-13 2001-07-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6391303B1 (en) 1996-11-18 2002-05-21 Emisphere Technologies, Inc. Methods and compositions for inducing oral tolerance in mammals
US6395774B1 (en) 1994-09-30 2002-05-28 Emisphere Technologies, Inc. Carbon-substituted diketopiperazine delivery systems
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US6440929B1 (en) 1998-07-27 2002-08-27 Emisphere Technologies, Inc. Pulmonary delivery of active agents
US6525020B2 (en) 1997-02-07 2003-02-25 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1296660A1 (en) * 2000-06-27 2003-04-02 Mi Tech Company Limited The controlled release preparation of insulin and its method
WO2003057650A2 (en) 2002-01-09 2003-07-17 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
US20030133953A1 (en) * 1992-06-15 2003-07-17 Emisphere Technologies, Inc. Active agent transport systems
US6623731B2 (en) 1995-03-31 2003-09-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6627228B1 (en) 1999-01-08 2003-09-30 Emisphere Technologies, Inc. Polymeric delivery agents and delivery agents compounds
US6642411B1 (en) 1998-07-27 2003-11-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6646162B2 (en) 1999-02-26 2003-11-11 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20030225300A1 (en) * 2001-04-19 2003-12-04 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US6663887B2 (en) 1993-04-22 2003-12-16 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6693208B2 (en) 1999-12-16 2004-02-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20040048777A1 (en) * 2000-06-29 2004-03-11 Weidner John J Compounds and compositions for delivering active agents
US20040077528A1 (en) * 1999-06-29 2004-04-22 Mannkind Corporation Purification and stabilization of peptide and protein pharmaceutical agents
US20040106825A1 (en) * 1999-04-05 2004-06-03 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6808707B2 (en) 2000-02-04 2004-10-26 Matrix Design Wound healing compositions and methods using tropoelastin and lysyl oxidase
US20050043239A1 (en) * 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
US20050088617A1 (en) * 2003-10-27 2005-04-28 Jen-Chuen Hsieh Method and apparatus for visual drive control
US20050153874A1 (en) * 2004-01-12 2005-07-14 Mannkind Corporation Method of reducing serum proinsulin levels in type 2 diabetics
US6960355B2 (en) 1996-03-29 2005-11-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20050261317A1 (en) * 2000-04-25 2005-11-24 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2005112633A2 (en) 2004-05-14 2005-12-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20050272638A1 (en) * 1998-08-07 2005-12-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20050277621A1 (en) * 2004-04-16 2005-12-15 Emisphere Technologies, Inc. 8-(2-Hydroxyphenoxy) octyldiethanolamine and salts thereof for delivery of active agents
US6991798B1 (en) 1998-08-07 2006-01-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20060106038A1 (en) * 2004-05-25 2006-05-18 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
US7084279B1 (en) 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
US20070004036A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for keratinocyte culture
US20070020191A1 (en) * 1999-06-29 2007-01-25 Mannkind Corporation Potentiation of glucose elimination
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US20070105199A1 (en) * 2005-10-21 2007-05-10 Wei Yan Methods for generating monovalent IgG
US20070128685A1 (en) * 2005-07-01 2007-06-07 Rodolfo Faudoa Methods and compositions for cell culture
US20070235365A1 (en) * 2004-03-12 2007-10-11 Biodel Inc. Rapid Acting Drug Delivery Compositions
US20080039368A1 (en) * 2006-04-12 2008-02-14 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2008022242A2 (en) 2006-08-18 2008-02-21 Emisphere Technologies, Inc. Synthesis of propyl phenoxy ethers and use as delivery agents
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
WO2008116141A1 (en) 2007-03-21 2008-09-25 Emisphere Technologies, Inc. Allylqxy and alkyloxy benzoic acid delivery agents
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20080287469A1 (en) * 2005-02-17 2008-11-20 Diacovo Thomas G Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
US20090092580A1 (en) * 2006-04-18 2009-04-09 Emisphere Technologies Inc. Dialkyl ether delivery agents
US20090137455A1 (en) * 2005-09-29 2009-05-28 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20090175840A1 (en) * 2008-01-04 2009-07-09 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
US20090220451A1 (en) * 2005-08-19 2009-09-03 Emisphere Technologies, Inc. Cyclopropyl compounds and compositions for delivering active agents
US20100074861A1 (en) * 2007-02-16 2010-03-25 Emisphere Technologies, Inc. Compounds having a cyclic moiety and compositions for delivering active agents
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20100227795A1 (en) * 2009-03-03 2010-09-09 Biodel Inc. Insulin formulations for rapid uptake
US20100256167A1 (en) * 2004-05-13 2010-10-07 Fowler Kerry W Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US20110044942A1 (en) * 2009-04-20 2011-02-24 Puri Kamal D Methods of treatment for solid tumors
EP2308479A2 (en) 2001-03-01 2011-04-13 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US8440677B2 (en) 2009-03-24 2013-05-14 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
US8691829B2 (en) 2009-07-21 2014-04-08 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
US8865730B2 (en) 2012-03-05 2014-10-21 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US9192675B2 (en) 2008-06-13 2015-11-24 Mankind Corporation Dry powder inhaler and system for drug delivery
US9220687B2 (en) 2008-12-29 2015-12-29 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
US9238070B2 (en) 2008-11-13 2016-01-19 Gilead Calistoga Llc Therapies for hematologic malignancies
US9241903B2 (en) 2006-02-22 2016-01-26 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US9283193B2 (en) 2005-09-14 2016-03-15 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US9364436B2 (en) 2011-06-17 2016-06-14 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
US9567337B2 (en) 2013-12-20 2017-02-14 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
US9630930B2 (en) 2009-06-12 2017-04-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9662461B2 (en) 2008-06-13 2017-05-30 Mannkind Corporation Dry powder drug delivery system and methods
US9675674B2 (en) 2004-08-23 2017-06-13 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US9700690B2 (en) 2002-03-20 2017-07-11 Mannkind Corporation Inhalation apparatus
US9706944B2 (en) 2009-11-03 2017-07-18 Mannkind Corporation Apparatus and method for simulating inhalation efforts
US9708327B2 (en) 2013-12-20 2017-07-18 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US9796688B2 (en) 2004-08-20 2017-10-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US9943571B2 (en) 2008-08-11 2018-04-17 Mannkind Corporation Use of ultrarapid acting insulin
US9983108B2 (en) 2009-03-11 2018-05-29 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10342938B2 (en) 2008-06-13 2019-07-09 Mannkind Corporation Dry powder drug delivery system
US10421729B2 (en) 2013-03-15 2019-09-24 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
US10456472B2 (en) 2007-02-08 2019-10-29 Emisphere Technologies, Inc. Phenylalkylcarboxylic acid delivery agents
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US10625034B2 (en) 2011-04-01 2020-04-21 Mannkind Corporation Blister package for pharmaceutical cartridges
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods

Citations (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL280826A (en) * 1962-07-11
NL280825A (en) * 1962-07-11
US2671451A (en) * 1952-06-16 1954-03-09 Stephen J Bolger Remedial pill
US2862918A (en) * 1956-03-12 1958-12-02 Glidden Co Acylated, isolated, partially-hydrolyzed, soya protein and process
US2868740A (en) * 1954-03-25 1959-01-13 Swift & Co Method of copolymerizing acrylic or methacrylic acid with proteinaceous material and product obtained
US2971916A (en) * 1957-01-30 1961-02-14 Ncr Co Microscopic capsules containing magnetizable material
US3016308A (en) * 1957-08-06 1962-01-09 Moore Business Forms Inc Recording paper coated with microscopic capsules of coloring material, capsules and method of making
US3057344A (en) * 1957-05-21 1962-10-09 Abella Carlos Alberto Capsule for the study of the digestive tract and method of using the same
GB929401A (en) * 1958-12-22 1963-06-19 Upjohn Co Encapsulated emulsions and processes for their preparation
FR1351358A (en) * 1958-12-22 1964-02-07 Ncr Co Process for forming impermeable coatings for particulate matter by liquid phase separation
US3170802A (en) * 1960-12-14 1965-02-23 Zh Noda Sangyo Kagaku Kenkyush Method for treatment of soybean proteins
US3190837A (en) * 1958-12-31 1965-06-22 Ncr Co Making individual capsules by dual deposition
FR1468601A (en) * 1958-12-22 1967-02-10 Ncr Co Process for forming protective coatings for solid and liquid particles
US3474777A (en) * 1966-02-10 1969-10-28 Amp Inc Method of administering therapeutic agents
US3565559A (en) * 1968-03-11 1971-02-23 Sumitomo Chemical Co Process for making microcapsules
US3576758A (en) * 1966-10-17 1971-04-27 Ncr Co Treatment of polypeptide-containing hydrophilic polymeric capsule wall material with uranium and vanadium compounds
FR2133926A1 (en) * 1971-04-21 1972-12-01 Yeda Research Develop Co
US3725113A (en) * 1970-12-17 1973-04-03 Research Corp Blood compatible microencapsulated detoxicants and method for making
DE2424169A1 (en) * 1973-05-17 1974-12-05 Little Inc A IMPLANT BODY AND METHOD OF ITS MANUFACTURING
US3937668A (en) * 1970-07-15 1976-02-10 Ilse Zolle Method for incorporating substances into protein microspheres
US3962416A (en) * 1971-01-25 1976-06-08 Sol Katzen Preserved nutrients and products
FR2326934A1 (en) * 1975-10-09 1977-05-06 Minnesota Mining & Mfg NEW PHARMACEUTICAL COMPOSITION BASED ON SERUM-ALBUMIN SPHERULES CONTAINING A MEDICINAL PRODUCT
US4048268A (en) * 1975-02-19 1977-09-13 Eli Lilly And Company Stabilization method
EP0000667A1 (en) * 1977-08-01 1979-02-07 Northwestern University Intravascularly-administrable, magnetically-localizable biodegradable carrier and process for its preparation
US4183849A (en) * 1975-01-15 1980-01-15 Nordisk Insulinlaboratorium Therapeutic insulin preparation and a process for the production of a stable insulin preparation with protracted effect
US4217370A (en) * 1977-08-25 1980-08-12 Blue Wing Corporation Lipid-containing feed supplements and foodstuffs
US4298002A (en) * 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
US4345588A (en) * 1979-04-23 1982-08-24 Northwestern University Method of delivering a therapeutic agent to a target capillary bed
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
DE3202255A1 (en) * 1981-01-27 1982-10-21 Japan Atomic Energy Research Institute, Tokyo METHOD FOR PRODUCING A COMPOSITE WITH LONG-TERM RELEASE
JPS5835111A (en) * 1981-08-25 1983-03-01 Kanebo Ltd Microcapsule with double-layer structure and its production
WO1984000964A1 (en) * 1982-09-02 1984-03-15 Otsuka Kagaku Yakuhin Process for preparing cephalosporin compounds
WO1984000965A1 (en) * 1982-09-09 1984-03-15 Otsuka Kagaku Yakuhin 2-substituted cephem derivatives and process for their preparation
EP0105804A2 (en) * 1982-09-30 1984-04-18 The University Of Rochester Human monoclonal antibodies against bacterial toxins
US4446138A (en) * 1982-02-10 1984-05-01 Pack Howard M Method and composition for reducing weight
US4450150A (en) * 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
EP0130162A2 (en) * 1983-06-22 1985-01-02 The Ohio State University Research Foundation Small particle formation and encapsulation
US4492684A (en) * 1983-06-08 1985-01-08 Connaught Laboratories Limited Slow release injectable insulin composition
WO1985002772A1 (en) * 1983-12-21 1985-07-04 Schroeder Ulf Diagnostic and contrast agent
WO1985004076A1 (en) * 1984-03-19 1985-09-26 Agne Persson Apparatus for feeding fish to a fish processing machine
FR2565102A1 (en) * 1984-06-05 1985-12-06 Paris Sud Universite BIODEGRADABLE MICROCAPSULES BASED ON SERUMALBUMIN, THEIR PREPARATION AND THEIR APPLICATION TO IN SITU LIBERATION OF MEDICUMENTS
US4608278A (en) * 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
US4613500A (en) * 1983-03-09 1986-09-23 Teijin Limited Powdery pharmaceutical composition for nasal administration
DE3612102A1 (en) * 1985-04-10 1986-10-16 Československá akademie věd, Prag/Praha SOLUBLE AND BIODEGRADABLE MIXED POLYMERS FOR THE BINDING OF BIOLOGICALLY ACTIVE SUBSTANCES AND METHOD FOR THE PRODUCTION THEREOF
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
US4673566A (en) * 1983-06-01 1987-06-16 Connaught Laboratories Limited Microencapsulation of living tissue and cells
EP0342056A2 (en) * 1988-05-13 1989-11-15 Unilever Plc Cosmetic composition
EP0342054A2 (en) * 1988-05-13 1989-11-15 Unilever Plc Cosmetic composition

Patent Citations (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2671451A (en) * 1952-06-16 1954-03-09 Stephen J Bolger Remedial pill
US2868740A (en) * 1954-03-25 1959-01-13 Swift & Co Method of copolymerizing acrylic or methacrylic acid with proteinaceous material and product obtained
US2862918A (en) * 1956-03-12 1958-12-02 Glidden Co Acylated, isolated, partially-hydrolyzed, soya protein and process
US2971916A (en) * 1957-01-30 1961-02-14 Ncr Co Microscopic capsules containing magnetizable material
US3057344A (en) * 1957-05-21 1962-10-09 Abella Carlos Alberto Capsule for the study of the digestive tract and method of using the same
US3016308A (en) * 1957-08-06 1962-01-09 Moore Business Forms Inc Recording paper coated with microscopic capsules of coloring material, capsules and method of making
FR1468601A (en) * 1958-12-22 1967-02-10 Ncr Co Process for forming protective coatings for solid and liquid particles
GB929401A (en) * 1958-12-22 1963-06-19 Upjohn Co Encapsulated emulsions and processes for their preparation
FR1351358A (en) * 1958-12-22 1964-02-07 Ncr Co Process for forming impermeable coatings for particulate matter by liquid phase separation
US3190837A (en) * 1958-12-31 1965-06-22 Ncr Co Making individual capsules by dual deposition
US3170802A (en) * 1960-12-14 1965-02-23 Zh Noda Sangyo Kagaku Kenkyush Method for treatment of soybean proteins
NL280825A (en) * 1962-07-11
NL280826A (en) * 1962-07-11
US3474777A (en) * 1966-02-10 1969-10-28 Amp Inc Method of administering therapeutic agents
US3576758A (en) * 1966-10-17 1971-04-27 Ncr Co Treatment of polypeptide-containing hydrophilic polymeric capsule wall material with uranium and vanadium compounds
US3565559A (en) * 1968-03-11 1971-02-23 Sumitomo Chemical Co Process for making microcapsules
US3937668A (en) * 1970-07-15 1976-02-10 Ilse Zolle Method for incorporating substances into protein microspheres
US3725113A (en) * 1970-12-17 1973-04-03 Research Corp Blood compatible microencapsulated detoxicants and method for making
US3962416A (en) * 1971-01-25 1976-06-08 Sol Katzen Preserved nutrients and products
FR2133926A1 (en) * 1971-04-21 1972-12-01 Yeda Research Develop Co
US3849550A (en) * 1971-04-21 1974-11-19 Yeda Res & Dev Therapeutic copolymer
DE2424169A1 (en) * 1973-05-17 1974-12-05 Little Inc A IMPLANT BODY AND METHOD OF ITS MANUFACTURING
US4450150A (en) * 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4183849A (en) * 1975-01-15 1980-01-15 Nordisk Insulinlaboratorium Therapeutic insulin preparation and a process for the production of a stable insulin preparation with protracted effect
US4048268A (en) * 1975-02-19 1977-09-13 Eli Lilly And Company Stabilization method
GB1567763A (en) * 1975-10-09 1980-05-21 Minnesota Mining & Mfg Albumin medicament carrier system
CA1077842A (en) * 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
US4147767A (en) * 1975-10-09 1979-04-03 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
FR2326934A1 (en) * 1975-10-09 1977-05-06 Minnesota Mining & Mfg NEW PHARMACEUTICAL COMPOSITION BASED ON SERUM-ALBUMIN SPHERULES CONTAINING A MEDICINAL PRODUCT
US4357259A (en) * 1977-08-01 1982-11-02 Northwestern University Method of incorporating water-soluble heat-sensitive therapeutic agents in albumin microspheres
EP0000667A1 (en) * 1977-08-01 1979-02-07 Northwestern University Intravascularly-administrable, magnetically-localizable biodegradable carrier and process for its preparation
US4217370A (en) * 1977-08-25 1980-08-12 Blue Wing Corporation Lipid-containing feed supplements and foodstuffs
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4345588A (en) * 1979-04-23 1982-08-24 Northwestern University Method of delivering a therapeutic agent to a target capillary bed
US4298002A (en) * 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
DE3202255A1 (en) * 1981-01-27 1982-10-21 Japan Atomic Energy Research Institute, Tokyo METHOD FOR PRODUCING A COMPOSITE WITH LONG-TERM RELEASE
US4483807A (en) * 1981-01-27 1984-11-20 Japan Atomic Energy Research Institute Process for producing a slow release composite
JPS5835111A (en) * 1981-08-25 1983-03-01 Kanebo Ltd Microcapsule with double-layer structure and its production
US4446138A (en) * 1982-02-10 1984-05-01 Pack Howard M Method and composition for reducing weight
WO1984000964A1 (en) * 1982-09-02 1984-03-15 Otsuka Kagaku Yakuhin Process for preparing cephalosporin compounds
WO1984000965A1 (en) * 1982-09-09 1984-03-15 Otsuka Kagaku Yakuhin 2-substituted cephem derivatives and process for their preparation
EP0105804A2 (en) * 1982-09-30 1984-04-18 The University Of Rochester Human monoclonal antibodies against bacterial toxins
US4613500A (en) * 1983-03-09 1986-09-23 Teijin Limited Powdery pharmaceutical composition for nasal administration
US4673566A (en) * 1983-06-01 1987-06-16 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4492684A (en) * 1983-06-08 1985-01-08 Connaught Laboratories Limited Slow release injectable insulin composition
EP0130162A2 (en) * 1983-06-22 1985-01-02 The Ohio State University Research Foundation Small particle formation and encapsulation
US4608278A (en) * 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
WO1985002772A1 (en) * 1983-12-21 1985-07-04 Schroeder Ulf Diagnostic and contrast agent
WO1985004076A1 (en) * 1984-03-19 1985-09-26 Agne Persson Apparatus for feeding fish to a fish processing machine
EP0170540A1 (en) * 1984-06-05 1986-02-05 Universite Paris-Sud (Paris Xi) Process for preparation of biodegradable microcapsules on the basis of serum albumin
US4666641A (en) * 1984-06-05 1987-05-19 Universite Paris-Sud (Paris Xi) Preparation of biodegradable microcapsules based on serum albumin
FR2565102A1 (en) * 1984-06-05 1985-12-06 Paris Sud Universite BIODEGRADABLE MICROCAPSULES BASED ON SERUMALBUMIN, THEIR PREPARATION AND THEIR APPLICATION TO IN SITU LIBERATION OF MEDICUMENTS
DE3612102A1 (en) * 1985-04-10 1986-10-16 Československá akademie věd, Prag/Praha SOLUBLE AND BIODEGRADABLE MIXED POLYMERS FOR THE BINDING OF BIOLOGICALLY ACTIVE SUBSTANCES AND METHOD FOR THE PRODUCTION THEREOF
EP0342056A2 (en) * 1988-05-13 1989-11-15 Unilever Plc Cosmetic composition
EP0342054A2 (en) * 1988-05-13 1989-11-15 Unilever Plc Cosmetic composition

Non-Patent Citations (142)

* Cited by examiner, † Cited by third party
Title
(1985) Chemical Abstracts , vol. No. 102(6), Abstract No. 50870d. *
(1985) Chemical Abstracts , vol. No. 105(1), Abstract No. 12027p. *
(1985) Chemical Abstracts, vol. No. 102(6), Abstract No. 50870d.
(1985) Chemical Abstracts, vol. No. 105(1), Abstract No. 12027p.
A. Yuki et al. (1969) Biochemical and Biophysical Research Communications , vol. 36(4), pp. 657 663. *
A. Yuki et al. (1969) Biochemical and Biophysical Research Communications, vol. 36(4), pp. 657-663.
A.M. Gol dovskii (1978) Zhurnal Evolyutsionnoi Biokhimii i Fiziologii , vol. 14(6), pp. 517 519. *
A.M. Gol'dovskii (1978) Zhurnal Evolyutsionnoi Biokhimii i Fiziologii, vol. 14(6), pp. 517-519.
A.T. Przybylski (1985) BioSystems , vol. 17, pp. 281 288. *
A.T. Przybylski (1985) BioSystems, vol. 17, pp. 281-288.
A.T. Przybylski et al. (1982) Die Naturwissenschafen , vol. 69, pp. 561 563. *
A.T. Przybylski et al. (1982) Die Naturwissenschafen, vol. 69, pp. 561-563.
A.T. Przybylski et al. (1984) Applied Biochemistry and Biotechnology , vol. 10, pp. 301 307. *
A.T. Przybylski et al. (1984) Applied Biochemistry and Biotechnology, vol. 10, pp. 301-307.
B. Heinz et al. (1981) BioSystems , vol. 14, pp. 33 40. *
B. Heinz et al. (1981) BioSystems, vol. 14, pp. 33-40.
C.B. Airaudo et al. (1987) Journal of Food Science , vol. 52(6), pp. 1750 1752. *
C.B. Airaudo et al. (1987) Journal of Food Science, vol. 52(6), pp. 1750-1752.
Chem. Abstract, vol. 80(9) Abst. No. 52392a. *
Chem. Abstracts vol. 105, entry 12027P. *
Chen et al. (1975) "Evidence for Hemiacetal Formation", Biochemistry, vol. 18, No. 5, pp. 921-926.
Chen et al. (1975) Evidence for Hemiacetal Formation , Biochemistry , vol. 18, No. 5, pp. 921 926. *
D.L. Rohlfing (1967) Archives of Biochemistry and Biophysics , vol. 118, pp. 468 474. *
D.L. Rohlfing (1967) Archives of Biochemistry and Biophysics, vol. 118, pp. 468-474.
D.L. Rohlfing (1970) Science , vol. 169, pp. 998 1000. *
D.L. Rohlfing (1970) Science, vol. 169, pp. 998-1000.
D.L. Rohlfing (1975) Origins of Life , vol. 6, pp. 203 209. *
D.L. Rohlfing (1975) Origins of Life, vol. 6, pp. 203-209.
D.L. Rohlfing et al. (1976) BioSystems , vol. 8, pp. 139 145. *
D.L. Rohlfing et al. (1976) BioSystems, vol. 8, pp. 139-145.
D.L. Rohlfing et al. Catalytic Activities of Thermal Polyanhydro Amino Acids , pp. 373 418 (1969). *
D.L. Rohlfing et al. Catalytic Activities of Thermal Polyanhydro-α-Amino Acids, pp. 373-418 (1969).
Davis et al. (1983) "Leucinal Inhibits . . . ", Pharmacology Biochemistry Behavior, vol. 19., pp. 791-794.
Davis et al. (1983) Leucinal Inhibits . . . , Pharmacology Biochemistry Behavior , vol. 19., pp. 791 794. *
E. Kokufta et al. (1984) BioSystems , vol. No. 16, pp. 175 181. *
E. Kokufta et al. (1984) BioSystems, vol. No. 16, pp. 175-181.
E. Kokufuta et al. (1984) BioSystems , vol. 16, pp. 175 181. *
E. Kokufuta et al. (1984) BioSystems, vol. 16, pp. 175-181.
Fasman et al. (1984) Biochemistry , vol. 3, No. 11, pp. 1665 1674. *
Fasman et al. (1984) Biochemistry, vol. 3, No. 11, pp. 1665-1674.
Fox, S.W., Molecular Evolution and The Origin of Life , New York: Marcel Decker (1972). *
Fox, S.W., Molecular Evolution and The Origin of Life, New York: Marcel Decker (1972).
G. Hennon et al. (1975) Biochimie , vol. 57, pp. 1395 1396. *
G. Hennon et al. (1975) Biochimie, vol. 57, pp. 1395-1396.
G. Krampitz et al. (1966) Naturwissenschaften , pp. 7 and 8. *
G. Krampitz et al. (1966) Naturwissenschaften, pp. 7 and 8.
G. Krampitz et al. (1967) Naturwissenschaften , pp. 516 517. *
G. Krampitz et al. (1967) Naturwissenschaften, pp. 516-517.
G. Krampitz et al. (1968) Naturwissenschaften , pp. 345 and 346. *
G. Krampitz et al. (1968) Naturwissenschaften, pp. 345 and 346.
G. Vaughan et al. (1987) BioSystems , vol. 20, pp. 219 223. *
G. Vaughan et al. (1987) BioSystems, vol. 20, pp. 219-223.
Harada et al., (1960) Archives of Biochemistry and Biophysics , vol. 86, pp. 274 280. *
Harada et al., (1960) Archives of Biochemistry and Biophysics, vol. 86, pp. 274-280.
Hare (1970) Etude Cenetique De La Polycondensation Thermique D x Amino Acides , vol. 169, pp. 330 339. *
Hare (1970) Etude Cenetique De La Polycondensation Thermique D'x -Amino Acides, vol. 169, pp. 330-339.
J. Miquel et al. (1971) Currents in Modern Biology , vol. 3, pp. 299 306. *
J. Miquel et al. (1971) Currents in Modern Biology, vol. 3, pp. 299-306.
J.C. Lacey, Jr. et al. (1979) BioSystems , vol. 11, pp. 1 7. *
J.C. Lacey, Jr. et al. (1979) BioSystems , vol. 11, pp. 9 17. *
J.C. Lacey, Jr. et al. (1979) BioSystems, vol. 11, pp. 1-7.
J.C. Lacey, Jr. et al. (1979) BioSystems, vol. 11, pp. 9-17.
J.R. Jungck et al. (1973) Naturwissenschaften , vol. 60, pp. 425 427. *
J.R. Jungck et al. (1973) Naturwissenschaften, vol. 60, pp. 425-427.
J.W. Ryan et al. (1973) BioSystems , vol. 5, pp. 115 118. *
J.W. Ryan et al. (1973) BioSystems, vol. 5, pp. 115-118.
K. Dose (1974) Origins of Life , vol. 5, pp. 239 252. *
K. Dose (1974) Origins of Life, vol. 5, pp. 239-252.
K. Harada et al. (1979) BioSystems , vol. 11, pp. 47 53. *
K. Harada et al. (1979) BioSystems, vol. 11, pp. 47-53.
K. Matsuno (1981) Biosystems , vol. 14, pp. 163 170. *
K. Matsuno (1981) Biosystems, vol. 14, pp. 163-170.
K. Matsuno (1982) BioSystems , vol. 15, pp. 1 11. *
K. Matsuno (1982) BioSystems, vol. 15, pp. 1-11.
K. Matsuno (1984) BioSystems , vol. 17, pp. 11 14. *
K. Matsuno (1984) BioSystems, vol. 17, pp. 11-14.
L.L. Hsu et al. (1971) Currents in Modern Biology , vol. 4, pp. 12 25. *
L.L. Hsu et al. (1971) Currents in Modern Biology, vol. 4, pp. 12-25.
L.L. Hsu et al. (1976) BioSystems , vol. 8, pp. 89 101. *
L.L. Hsu et al. (1976) BioSystems, vol. 8, pp. 89-101.
M. Martinez Luque Romero et al. (1986) BioSystems , vol. 19, pp. 267 272. *
M. Martinez Luque-Romero et al. (1986) BioSystems, vol. 19, pp. 267-272.
M.A. Saunders et al. (1974) BioSystems , vol. 6, pp. 81 92. *
M.A. Saunders et al. (1974) BioSystems, vol. 6, pp. 81-92.
M.R. Heinrich et al. (1969) Archives of Biochemistry and Biophysics , vol. 130, pp. 441 448. *
M.R. Heinrich et al. (1969) Archives of Biochemistry and Biophysics, vol. 130, pp. 441-448.
M.V. Vol kenshtein (1989) Molekulyarnaya Biologiya , vol. 23(1), pp. 23 37. *
M.V. Vol'kenshtein (1989) Molekulyarnaya Biologiya, vol. 23(1), pp. 23-37.
Miguel et al., Acidic Proteinoids and Histone like Porteinoids , pp. 302 306 (1971). *
Miguel et al., Acidic Proteinoids and Histone-like Porteinoids, pp. 302-306 (1971).
P. Melius (1979) BioSystems , vol. 11, pp. 123 132. *
P. Melius (1979) BioSystems, vol. 11, pp. 123-132.
P. Melius et al. (1975) Bioorganic Chemistry , vol. 4, pp. 385 391. *
P. Melius et al. (1975) Bioorganic Chemistry, vol. 4, pp. 385-391.
P. Melius et al. (1987) BioSystems , vol. 20, pp. 213 217. *
P. Melius et al. (1987) BioSystems, vol. 20, pp. 213-217.
P.E. Sokol (1974) Journal of the American Oil Chemists Society , vol. 52, pp. 101 102. *
P.E. Sokol (1974) Journal of the American Oil Chemists'Society, vol. 52, pp. 101-102.
P.G. Olafsson et al. (1971) Polymer Letters , vol. 9, pp. 521 528. *
P.G. Olafsson et al. (1971) Polymer Letters, vol. 9, pp. 521-528.
R.D. Phillips et al. (1974) Int. J. Peptide Protein Res ., vol. 6, pp. 309 319. *
R.D. Phillips et al. (1974) Int. J. Peptide Protein Res., vol. 6, pp. 309-319.
S. Andini et al. (1975) Origins of Life , vol. 6, pp. 147 153. *
S. Andini et al. (1975) Origins of Life, vol. 6, pp. 147-153.
S. Brooke et al. (1977) BioSystems , vol. 9, pp. 1 22. *
S. Brooke et al. (1977) BioSystems, vol. 9, pp. 1-22.
S. Gurrieri et al. (1973) Thermochimica Acta , vol. 7, pp. 231 239. *
S. Gurrieri et al. (1973) Thermochimica Acta, vol. 7, pp. 231-239.
S.W. Fox (1976) Origins of Life , vol. 7, pp. 49 68. *
S.W. Fox (1976) Origins of Life, vol. 7, pp. 49-68.
S.W. Fox (1980) Naturwissenschaften , vol. 67, pp. 378 383. *
S.W. Fox (1980) Naturwissenschaften, vol. 67, pp. 378-383.
S.W. Fox (1984) Origins of Life , vol. 14, pp. 485 488. *
S.W. Fox (1984) Origins of Life, vol. 14, pp. 485-488.
S.W. Fox et al. (1960) Archives of Biochemistry and Biophysics , vol. 86, pp. 281 285. *
S.W. Fox et al. (1960) Archives of Biochemistry and Biophysics, vol. 86, pp. 281-285.
S.W. Fox et al. (1968) Biochim. Biophys. Acta , vol. 160, pp. 246 249. *
S.W. Fox et al. (1968) Biochim. Biophys. Acta, vol. 160, pp. 246-249.
S.W. Fox et al. (1974) Origins of Life , vol. 5, pp. 227 237. *
S.W. Fox et al. (1974) Origins of Life, vol. 5, pp. 227-237.
S.W. Fox et al. (1976) BioSystems , vol. 8, pp. 40 44. *
S.W. Fox et al. (1976) BioSystems, vol. 8, pp. 40-44.
T. Nakashima et al. (1980) J. Mol. Evol ., vol. 15, pp. 161 168. *
T. Nakashima et al. (1980) J. Mol. Evol., vol. 15, pp. 161-168.
T. Nakashima et al. (1981) BioSystems , vol. 14, pp. 151 161. *
T. Nakashima et al. (1981) BioSystems, vol. 14, pp. 151-161.
T.V. Waehneldt et al. (1968) Biochim. Biophys. Acta , vol. 160, pp. 239 245. *
T.V. Waehneldt et al. (1968) Biochim. Biophys. Acta, vol. 160, pp. 239-245.
Tschager et al. (1989) Milchwirtschaftliche Berichte , vol. 95, pp. 79 83. *
Tschager et al. (1989) Milchwirtschaftliche Berichte, vol. 95, pp. 79-83.
V.J.A. Novak (1984) Origins of Life , vol. 14, pp. 513 522. *
V.J.A. Novak (1984) Origins of Life, vol. 14, pp. 513-522.
W.D. Snyder et al. (1975) BioSystems , vol. 7, pp. 222 229. *
W.D. Snyder et al. (1975) BioSystems, vol. 7, pp. 222-229.
W.W. McAlhaney et al. (1976) BioSystems , vol. 8, pp. 45 50. *
W.W. McAlhaney et al. (1976) BioSystems, vol. 8, pp. 45-50.
Y. Ishima et al. (1981), BioSystems , vol. 14, pp. 243 251. *
Y. Ishima et al. (1981), BioSystems, vol. 14, pp. 243-251.
Z. Masinovsky et al. (1989) BioSystems , vol. 22, pp. 305 310. *
Z. Masinovsky et al. (1989) BioSystems, vol. 22, pp. 305-310.
Zulaski et al. (1983) "New Carboxyalkyl Inhibitors of Brain Enkenphalinase", J. Med. Chem., 26, pp. 60-65.
Zulaski et al. (1983) New Carboxyalkyl Inhibitors of Brain Enkenphalinase , J. Med. Chem ., 26, pp. 60 65. *

Cited By (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133953A1 (en) * 1992-06-15 2003-07-17 Emisphere Technologies, Inc. Active agent transport systems
US6916489B2 (en) 1992-06-15 2005-07-12 Emisphere Technologies, Inc. Active agent transport systems
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6268053B1 (en) 1993-03-09 2001-07-31 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6663887B2 (en) 1993-04-22 2003-12-16 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6906030B2 (en) 1994-09-30 2005-06-14 Emisphere Technologies, Inc. Carbon-substituted diketopiperazine delivery systems
US7276534B2 (en) 1994-09-30 2007-10-02 Emisphere Technologies, Inc. Carbon-substituted diketopiperazine delivery systems
US20090238882A1 (en) * 1994-09-30 2009-09-24 Mannkind Corporation Carbon-substituted diketopiperazine delivery systems
US6395774B1 (en) 1994-09-30 2002-05-28 Emisphere Technologies, Inc. Carbon-substituted diketopiperazine delivery systems
US8133514B2 (en) 1994-09-30 2012-03-13 Mannkind Corporation Carbon-substituted diketopiperazine delivery systems
US20030198658A1 (en) * 1994-09-30 2003-10-23 Emisphere Technologies, Inc. Carbon-substituted diketopiperazine delivery systems
US6623731B2 (en) 1995-03-31 2003-09-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20040096403A1 (en) * 1995-05-15 2004-05-20 Mannkind Corporation Method for drug delivery to the pulmonary system
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US8394414B2 (en) 1995-05-15 2013-03-12 Mannkind Corporation Method for drug delivery to the pulmonary system
US6960355B2 (en) 1996-03-29 2005-11-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6391303B1 (en) 1996-11-18 2002-05-21 Emisphere Technologies, Inc. Methods and compositions for inducing oral tolerance in mammals
US6525020B2 (en) 1997-02-07 2003-02-25 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6642411B1 (en) 1998-07-27 2003-11-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6440929B1 (en) 1998-07-27 2002-08-27 Emisphere Technologies, Inc. Pulmonary delivery of active agents
US20050272638A1 (en) * 1998-08-07 2005-12-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US7744910B2 (en) 1998-08-07 2010-06-29 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20070010422A1 (en) * 1998-08-07 2007-01-11 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US7186414B2 (en) 1998-08-07 2007-03-06 Emisphere Technologies, Inc Compounds and compositions for delivering active agents
US6991798B1 (en) 1998-08-07 2006-01-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US7727558B2 (en) 1999-01-08 2010-06-01 Emisphere Technologies, Inc. Polymeric delivery agents and delivery agent compounds
US20070141022A1 (en) * 1999-01-08 2007-06-21 Emisphere Technologies, Inc. Polymeric delivery agents and delivery agent compounds
US20030232085A1 (en) * 1999-01-08 2003-12-18 Emisphere Technologies, Inc. Polymeric delivery agents and delivery agent compounds
US7208483B2 (en) 1999-01-08 2007-04-24 Emisphere Technologies, Inc. Polymeric delivery agents and delivery agent compounds
US6627228B1 (en) 1999-01-08 2003-09-30 Emisphere Technologies, Inc. Polymeric delivery agents and delivery agents compounds
US7084279B1 (en) 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
US6646162B2 (en) 1999-02-26 2003-11-11 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US8207227B2 (en) 1999-04-05 2012-06-26 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US7384982B2 (en) 1999-04-05 2008-06-10 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US20080269134A1 (en) * 1999-04-05 2008-10-30 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US7659311B2 (en) 1999-04-05 2010-02-09 Novartis Ag Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US20100099621A1 (en) * 1999-04-05 2010-04-22 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US20040106825A1 (en) * 1999-04-05 2004-06-03 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US8003697B2 (en) 1999-04-05 2011-08-23 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US8658695B2 (en) 1999-04-05 2014-02-25 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US20070020191A1 (en) * 1999-06-29 2007-01-25 Mannkind Corporation Potentiation of glucose elimination
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US7648960B2 (en) 1999-06-29 2010-01-19 Mannkind Corporation Method for delivery of monomeric or dimeric insulin complexed to diketopiperazine microparticles
US20100086609A1 (en) * 1999-06-29 2010-04-08 Mannkind Corporation Methods and Compositions for Delivering Peptides
US20040077528A1 (en) * 1999-06-29 2004-04-22 Mannkind Corporation Purification and stabilization of peptide and protein pharmaceutical agents
US9801925B2 (en) 1999-06-29 2017-10-31 Mannkind Corporation Potentiation of glucose elimination
US20110105391A1 (en) * 1999-06-29 2011-05-05 Mannkind Corporation Methods and Compositions for Delivering Peptides
US7943178B2 (en) 1999-06-29 2011-05-17 Mannkind Corporation Methods and compositions for delivering peptides
US8389470B2 (en) 1999-06-29 2013-03-05 Mannkind Corporation Methods and compositions for delivering peptides
US6693208B2 (en) 1999-12-16 2004-02-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20050042274A1 (en) * 1999-12-16 2005-02-24 David Gschneidner Compounds and compositions for delivering active agents
WO2001051454A1 (en) 2000-01-13 2001-07-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20050175600A1 (en) * 2000-02-04 2005-08-11 Ensley Burt D. Wound healing compositions and methods using tropoelastin and lysyl oxidase
US20080038243A1 (en) * 2000-02-04 2008-02-14 Matrix Design Wound healing compositions and methods using tropoelastin and lysyl oxidase
US6808707B2 (en) 2000-02-04 2004-10-26 Matrix Design Wound healing compositions and methods using tropoelastin and lysyl oxidase
US20100168139A1 (en) * 2000-04-25 2010-07-01 Chanchal Sadhu Inhibitors of human phosphatidylinositol 3-kinase delta
US10695349B2 (en) 2000-04-25 2020-06-30 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US8623881B2 (en) 2000-04-25 2014-01-07 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US8637533B2 (en) 2000-04-25 2014-01-28 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US8138195B2 (en) 2000-04-25 2012-03-20 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US10398695B2 (en) 2000-04-25 2019-09-03 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US20100152211A1 (en) * 2000-04-25 2010-06-17 Chanchal Sadhu Inhibitors of human phosphatidylinositol 3-kinase delta
US8653077B2 (en) 2000-04-25 2014-02-18 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US10010550B2 (en) 2000-04-25 2018-07-03 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US8492389B2 (en) 2000-04-25 2013-07-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US20050261317A1 (en) * 2000-04-25 2005-11-24 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US9487772B2 (en) 2000-04-25 2016-11-08 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1296660A4 (en) * 2000-06-27 2005-04-13 Mi Tech Company Ltd The controlled release preparation of insulin and its method
EP1296660A1 (en) * 2000-06-27 2003-04-02 Mi Tech Company Limited The controlled release preparation of insulin and its method
US20040048777A1 (en) * 2000-06-29 2004-03-11 Weidner John J Compounds and compositions for delivering active agents
US7351741B2 (en) 2000-06-29 2008-04-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP2308479A2 (en) 2001-03-01 2011-04-13 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20030225300A1 (en) * 2001-04-19 2003-12-04 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
WO2003057650A2 (en) 2002-01-09 2003-07-17 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
EP2272501A1 (en) 2002-01-09 2011-01-12 Emisphere Technologies, Inc. Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate
US9700690B2 (en) 2002-03-20 2017-07-11 Mannkind Corporation Inhalation apparatus
US20050043239A1 (en) * 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
US20100029693A1 (en) * 2003-08-14 2010-02-04 Jason Douangpanya Novel pi3k delta inhibitors and methods of use thereof
US20050088617A1 (en) * 2003-10-27 2005-04-28 Jen-Chuen Hsieh Method and apparatus for visual drive control
US20050153874A1 (en) * 2004-01-12 2005-07-14 Mannkind Corporation Method of reducing serum proinsulin levels in type 2 diabetics
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20070235365A1 (en) * 2004-03-12 2007-10-11 Biodel Inc. Rapid Acting Drug Delivery Compositions
US8933023B2 (en) 2004-03-12 2015-01-13 Biodel Inc. Rapid acting injectable insulin compositions
US20090192075A1 (en) * 2004-03-12 2009-07-30 Biodel Inc. Amylin Formulations
US20050277621A1 (en) * 2004-04-16 2005-12-15 Emisphere Technologies, Inc. 8-(2-Hydroxyphenoxy) octyldiethanolamine and salts thereof for delivery of active agents
US7217703B2 (en) 2004-04-16 2007-05-15 Emisphere Technologies, Inc. 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
US8207153B2 (en) 2004-05-13 2012-06-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
USRE44638E1 (en) 2004-05-13 2013-12-10 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US10906907B2 (en) 2004-05-13 2021-02-02 Icos Corporation Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof
US7932260B2 (en) 2004-05-13 2011-04-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US20100256167A1 (en) * 2004-05-13 2010-10-07 Fowler Kerry W Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US9149477B2 (en) 2004-05-13 2015-10-06 Icos Corporation 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
US8586597B2 (en) 2004-05-13 2013-11-19 Icos Corporation 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
USRE44599E1 (en) 2004-05-13 2013-11-12 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US8993583B2 (en) 2004-05-13 2015-03-31 Icos Corporation 5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta
US8779131B2 (en) 2004-05-13 2014-07-15 Icos Corporation 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
US10336756B2 (en) 2004-05-13 2019-07-02 Icos Corporation (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta
US8980901B2 (en) 2004-05-13 2015-03-17 Icos Corporation 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta
WO2005112633A2 (en) 2004-05-14 2005-12-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20060106038A1 (en) * 2004-05-25 2006-05-18 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
US9796688B2 (en) 2004-08-20 2017-10-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US10130685B2 (en) 2004-08-23 2018-11-20 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US9675674B2 (en) 2004-08-23 2017-06-13 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US20080287469A1 (en) * 2005-02-17 2008-11-20 Diacovo Thomas G Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
US20070128685A1 (en) * 2005-07-01 2007-06-07 Rodolfo Faudoa Methods and compositions for cell culture
US20070004036A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for keratinocyte culture
US8541362B2 (en) 2005-08-19 2013-09-24 Emisphere Technologies, Inc. Cyclopropyl compounds and compositions for delivering active agents
US20090220451A1 (en) * 2005-08-19 2009-09-03 Emisphere Technologies, Inc. Cyclopropyl compounds and compositions for delivering active agents
US10143655B2 (en) 2005-09-14 2018-12-04 Mannkind Corporation Method of drug formulation
US9283193B2 (en) 2005-09-14 2016-03-15 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US9717689B2 (en) 2005-09-14 2017-08-01 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US9446001B2 (en) 2005-09-14 2016-09-20 Mannkind Corporation Increasing drug affinity for crystalline microparticle surfaces
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US20090137455A1 (en) * 2005-09-29 2009-05-28 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070105199A1 (en) * 2005-10-21 2007-05-10 Wei Yan Methods for generating monovalent IgG
US8193322B2 (en) 2005-10-21 2012-06-05 Amgen Inc. Methods for generating monovalent IgG
US10130581B2 (en) 2006-02-22 2018-11-20 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US9241903B2 (en) 2006-02-22 2016-01-26 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20080039368A1 (en) * 2006-04-12 2008-02-14 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7718609B2 (en) 2006-04-12 2010-05-18 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20090092580A1 (en) * 2006-04-18 2009-04-09 Emisphere Technologies Inc. Dialkyl ether delivery agents
US8703821B2 (en) 2006-04-18 2014-04-22 Emisphere Technologies Inc. Dialkyl ether delivery agents
WO2008022242A2 (en) 2006-08-18 2008-02-21 Emisphere Technologies, Inc. Synthesis of propyl phenoxy ethers and use as delivery agents
US11253596B2 (en) 2007-02-08 2022-02-22 Novo Nordisk North America Operations A/S Phenylalkylcarboxylic acid delivery agents
US10456472B2 (en) 2007-02-08 2019-10-29 Emisphere Technologies, Inc. Phenylalkylcarboxylic acid delivery agents
US20100074861A1 (en) * 2007-02-16 2010-03-25 Emisphere Technologies, Inc. Compounds having a cyclic moiety and compositions for delivering active agents
US8383852B2 (en) 2007-02-16 2013-02-26 Emisphere Technologies, Inc. Compounds having a cyclic moiety and compositions for delivering active agents
WO2008116141A1 (en) 2007-03-21 2008-09-25 Emisphere Technologies, Inc. Allylqxy and alkyloxy benzoic acid delivery agents
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20090175840A1 (en) * 2008-01-04 2009-07-09 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
US10201672B2 (en) 2008-06-13 2019-02-12 Mannkind Corporation Dry powder inhaler and system for drug delivery
US10342938B2 (en) 2008-06-13 2019-07-09 Mannkind Corporation Dry powder drug delivery system
US9511198B2 (en) 2008-06-13 2016-12-06 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9446133B2 (en) 2008-06-13 2016-09-20 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9339615B2 (en) 2008-06-13 2016-05-17 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9662461B2 (en) 2008-06-13 2017-05-30 Mannkind Corporation Dry powder drug delivery system and methods
US10751488B2 (en) 2008-06-13 2020-08-25 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9192675B2 (en) 2008-06-13 2015-11-24 Mankind Corporation Dry powder inhaler and system for drug delivery
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US10675421B2 (en) 2008-06-20 2020-06-09 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US9943571B2 (en) 2008-08-11 2018-04-17 Mannkind Corporation Use of ultrarapid acting insulin
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
US9238070B2 (en) 2008-11-13 2016-01-19 Gilead Calistoga Llc Therapies for hematologic malignancies
US10154998B2 (en) 2008-11-13 2018-12-18 Gilead Calistoga Llc Therapies for hematologic malignancies
US9220687B2 (en) 2008-12-29 2015-12-29 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US10172850B2 (en) 2008-12-29 2019-01-08 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9655850B2 (en) 2008-12-29 2017-05-23 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US20100227795A1 (en) * 2009-03-03 2010-09-09 Biodel Inc. Insulin formulations for rapid uptake
US9983108B2 (en) 2009-03-11 2018-05-29 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8440677B2 (en) 2009-03-24 2013-05-14 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
US20110044942A1 (en) * 2009-04-20 2011-02-24 Puri Kamal D Methods of treatment for solid tumors
US8546409B2 (en) 2009-04-20 2013-10-01 Gilead Calistoga Llc Methods of treatment for solid tumors
US9630930B2 (en) 2009-06-12 2017-04-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US8691829B2 (en) 2009-07-21 2014-04-08 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
US9706944B2 (en) 2009-11-03 2017-07-18 Mannkind Corporation Apparatus and method for simulating inhalation efforts
US10625034B2 (en) 2011-04-01 2020-04-21 Mannkind Corporation Blister package for pharmaceutical cartridges
US10130709B2 (en) 2011-06-17 2018-11-20 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US9364436B2 (en) 2011-06-17 2016-06-14 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US10258664B2 (en) 2011-10-24 2019-04-16 Mannkind Corporation Methods and compositions for treating pain
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
US9610351B2 (en) 2011-10-24 2017-04-04 Mannkind Corporation Methods and compositions for treating pain
US9469643B2 (en) 2012-03-05 2016-10-18 Gilead Calistoga, LLC. Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US10730879B2 (en) 2012-03-05 2020-08-04 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US8865730B2 (en) 2012-03-05 2014-10-21 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
US10421729B2 (en) 2013-03-15 2019-09-24 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
US10047060B2 (en) 2013-12-20 2018-08-14 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
US10442805B2 (en) 2013-12-20 2019-10-15 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US10414737B2 (en) 2013-12-20 2019-09-17 Gilead Sciences, Inc. Process methods for phosphatidylinositol 3-kinase inhibitors
US9567337B2 (en) 2013-12-20 2017-02-14 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
US10954199B2 (en) 2013-12-20 2021-03-23 Gilead Sciences, Inc. Process methods for phosphatidylinositol 3-kinase inhibitors
US10059677B2 (en) 2013-12-20 2018-08-28 Gilead Calistoga Llc Process for preparing phosphatidylinositol 3-kinase inhibitors and intermediates thereof
US9708327B2 (en) 2013-12-20 2017-07-18 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler

Similar Documents

Publication Publication Date Title
USRE35862E (en) Delivery systems for pharmacological agents encapsulated with proteinoids
US4925673A (en) Delivery systems for pharmacological agents encapsulated with proteinoids
US4983402A (en) Orally administerable ANF
US4976968A (en) Anhydrous delivery systems for pharmacological agents
Ramadas et al. Lipoinsulin encapsulated alginate-chitosan capsules: intestinal delivery in diabetic rats
CA2415414C (en) Particulate vectors for improving oral absorption of active principles
US5352461A (en) Self assembling diketopiperazine drug delivery system
JPH07508004A (en) Proteinoid carriers and their production and use methods
US5081156A (en) Sustained-release preparation
JPH0150686B2 (en)
WO1997049386A1 (en) Oral delivery of peptides
US20110244005A1 (en) Controlled release cgrp delivery composition for cardiovascular and renal indications
JPH09501652A (en) Pharmaceutical composition containing heparin, heparin fragments or their derivatives in combination with glycerol ester
KR950009089B1 (en) Delivery systems for pharmaceutical agents
DE3745075C2 (en) Therapeutic agent encapsulated in proteinoid microspheres
PT86571B (en) METHOD FOR THE MICROENCAPSULATION OF PHARMACOLOGICAL AGENTS AND PROCESS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS CONTAINING THESE AGENTS
DE3790487C2 (en) Microencapsulation for pharmacological compositions
CA2297025A1 (en) Polymer based pharmaceutical compositions for targeted delivery of biologically active agents
Vyas et al. Enteric spherules diastase in enzyme preparations
JPH1121250A (en) Pharmaceutical preparation
JPH0912467A (en) Alpha2-macroglobulin inclusion complex for application to mucosa
TW201125578A (en) A sustained preparation of Factor IX

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: MHR INSTITUTIONAL PARTNERS IIA LP, NEW YORK

Free format text: SECURITY AGREEMENT;ASSIGNOR:EMISPHERE TECHNOLOGIES, INC.;REEL/FRAME:016593/0703

Effective date: 20050926